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ABSTRACT 
Nucleic Acids are the most important macromolecules in living systems. They directly 
participate in storing, transferring and expressing the genetic information, thereby controlling and 
regulating the function of living systems. Therefore, nucleic acid research will give us molecular 
insights into lives. Meanwhile, many novel research methods based on nucleic acids have been 
developed. Moreover, nucleic acid-based therapeutics have been developed rapidly over the past 
several years, leading to a revolution on drug discovery and disease study at the molecular level 
and the genetic level. Consequently, the structure and function studies on nucleic acids and protein-
nucleic acid complexes have attracted tremendous research attention, especially in medical science 
and biological chemistry.  
Since oxygen and selenium are in the same main group in the periodic table, we anticipate 
oxygen atoms on nucleic acids can be replaced by selenium atoms without significant perturbations 
on structure and function. Previously, we successfully completed the chemical and enzymatic 
synthesis of Se-modified nucleic acids (SeNA) with selenium substitutions at various positions. 
Indeed, we have demonstrated that the Se-modifications would not lead to significant changes in 
the structure. In addition, SeNA can largely facilitate nucleic acid-protein X-ray crystallography, 
and its unique properties may lead to many other potential applications, such as gene silencing, 
therapeutics and cellular imaging. This dissertation has explored potential applications of SeNA, 
including therapeutic and biochemical research, via structural and functional studies. We 
demonstrated that SeNA has great potential for antisense drug discovery because of its stronger 
nuclease resistance, better compatibility with RNase H and more efficient gene silencing in cells. 
SeNA could also be applied in cellular imaging via micro-X-ray fluorescence (microXRF), which 
allowed us to establish a novel approach to image mRNA transportation in cells. With this 
approach, we have successfully monitored the GFP mRNA in HeLa cell. Furthermore, we found 
that SeNA doesn’t perturb the structure of DNA/DNA polymerase complex, which allows an 
accurate structural determination of protein-nucleic acid complexes and provides a bright future 
on X-ray crystallography of nucleic acids and their protein complexes. 
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1 GENERAL INTRODUCTION  
1.1 Nucleic Acids for Biofunction Studies and Drug Discovery  
Nucleic acids are the storage and carrier of genetic information and directly participate in 
gene replication, transcription, and expression1-2. The control of nucleic acids can lead to the 
regulation of genetic information flow and gene expression. In addition, many non-coding RNAs, 
like microRNA and ribosomal RNA, participate in signal transduction directly by regulatory 
functions3-4. Moreover, nucleic acid-based therapeutic strategies are effective tools in drug 
discovery and disease study at the molecular level as well as the genetic level5-6. In these 
therapeutic strategies, the gene, instead of a protein product, is recognized as drug targets and the 
modified oligonucleotides (including DNAs and RNAs) are applied as drug candidates. Therefore, 
nucleic acids related research is essential for better understanding of diseases and identifying novel 
drug candidate and target for the development of therapeutics with high efficiency to treat some 
world-wide diseases. Because of the advantages of low toxicity, notable efficacy, and high 
specificity, numerous nucleic acid-based potential therapeutics are under development or in 
clinical trials, including nucleoside analog, antisense oligonucleotides, siRNAs, miRNAs, 
aptamers and ribozymes and DNazymes7-8. Instead of the traditional attacking of aberrant proteins, 
modulating expression of specific diseases’ gene by these nucleic acids therapies can lead to better 
treatment. Research activities in this area require further development of new nucleic acid analogs 
with improved properties. 
On the other hand, the unique structures of DNA and RNA provide nucleic acids multiple 
functions and properties. The negative charges on phosphate groups make nucleic acids soluble in 
water, and the hydrophobic nucleobases in the center can form Watson-Crick hydrogen bonds. 
Additionally, the complicated RNA secondary and tertiary structures generate enzyme-like 
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catalytic functions. Recently, X-ray crystallography has been the most powerful technical tool to 
provide researchers detailed 3-D structural information of nucleic acids at the atomic level, which 
is helpful for us to discover new drug candidate and understand nucleic acids related biological 
processes mechanisms, such as DNA replication, ribozyme catalysis, DNA transcription, and RNA 
translation9-10. Despite the bottle-necks of nucleic acid crystallography and phase problem, it is 
greatly promising for researchers to rely on it for nucleic acid function study and gene therapy 
development11-12.  
 
1.2 Selenium Substituted Nucleic Acids for Structural Determination 
In the past half century, X-ray crystallographic technologies have largely facilitated the 
structure determination of biological macromolecules, including nucleic acids and protein-nucleic 
acid complexes. More and more structures of nucleic acids and nucleic acid-protein complexes 
have been determined. At the same time, there are many potential nucleic acid-based therapeutics 
in development, and some of them have already been approved by FDA13. These investigations 
make structural and functional studies of nucleic acid-protein complexes an increasingly active 
research field, thereby demanding new methodologies especially novel strategies for nucleic acid 
X-ray crystallography, such as the selenium-atom-specific replacement of oxygen atoms in nucleic 
acids14. 
However, compared with protein crystallography, the process of structure determination of 
nucleic acids and nucleic acid/protein complexes is much slower. Figure 1.1 indicates the number 
of total released structures in protein data bank (PDB) since 2001. It is obvious that the increase 
of nucleic acids related structures determination is much slower than the structure of protein only. 
The reason is that there are some unique challenges for nucleic acid X-ray crystallography. The 
3 
first challenge is to obtain the crystals of nucleic acids. Proteins have a variety of structural and 
chemical functionalities on its surface to enable molecular interaction and could easily pack to 
crystals. However, the surface of nucleic acid has a lot of negative charges and repetitive phosphate 
functionalities. And there are also many nucleobases which are much alike with each other with 
aromatic rings. Compared with protein, these intrinsic charges, as well as its structural dynamics, 
make the crystal packing of DNA and RNA molecules much more difficult14. The crystallization 
condition and buffer screening process are labor intensive, and the formation of high-quality 
crystals could be hard and time-consuming. These issues have significantly slowed down the 
structure determination of nucleic acids and protein-nucleic acid complexes.   
 
 
Figure 1.1 Total released structures in PDB each year since 2001 
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Besides the difficulties of crystal growth, phase problem (phasing or phase determination) 
is another challenge need to be overcome. During the diffraction data analysis, the application of 
a Fourier transformation is required to construct the electron density map of the biological 
macromolecule investigated. In the Fourier transformation, both structure factors amplitude F and 
phase of the reflection α are needed to calculate the electron density. The former can be measured 
during the X-ray diffraction experiment. However, the phase information is missing which is 
critical to producing the correct crystal structure. Several different strategies were applied to 
address this issue, such as molecular replacement (MR), isomorphism replacement (SIR; MIR) 
and anomalous dispersion techniques including single- and multi-wavelength anomalous 
diffraction (SAD and MAD). With an available similar model, MR should be the most convenient 
and fastest method which don’t need to obtain a heavy-atom derivative. However, for novel 
structures, especially for nucleic acids containing highly repetitive and stacked units15, molecular 
replacement could be very difficult. A suitable model can hardly be found. So heavy-atom 
derivatization method is the only way to solve the phase problem for most nucleic acid molecules. 
The isomorphous replacement was successfully used in protein crystallography by soaking and 
co-crystallization with heavy metal cations. However, this strategy can often cause random 
hydrolysis of the phosphate backbone in nucleic acid crystallization because normally heavy metal 
cations are Lewis acids. Moreover, this method requires preparing many isomorphous native 
crystals and heavy atom derivatives to determine the structures. Compared with isomorphous 
replacement, the SAD and MAD technique could be a better way to solve the phase problem of 
nucleic acids and nucleic acid-protein complexes, which only requires one single crystal in order 
to obtain all diffraction information needed for the structure determination.  
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Figure 1.2 Se-atom-specific modifications on nucleic acids 
 
To solve these problems in nucleic acid X-ray crystallography, our research group has 
pioneered and developed the selenium substituted nucleic acids for structure and function studies 
(Figure 1.2), establishing chemical structural biology of nucleic acids. Based on our previous 
research, Se-atom-specific modifications will not cause significant structure and function 
perturbations and could tailor the local structure and molecular dynamics of DNA and RNA and 
to accelerate the crystallization process of these molecules. During the past several years, the 
selenium atom, in the same main group of oxygen, has been introduced to many different locations 
of nucleotides, including phosphate groups, sugar moiety, and nucleobases, to study its unique 
structural and functional effects on nucleic acids. 
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Figure 1.3 Crystal structure of RNase H complexed with the Se-modified DNA and RNA 
duplex. 
(A) The overall structure of Se-DNA/RNA/RNase H ternary complex determined at 1.80 Å 
resolution (D132N mutant; PDB ID: 3TWH). Protein is in green; RNA and DNA strands are in 
pink and orange, respectively. The red and yellow spheres are Mg2+ ions and Se atoms, respectively. 
The cleavage site is indicated by the arrow. 
(B) Sequences of the native and modified DNAs and RNAs. SeG and SG represent 6-Se-G and 6-
S-G, respectively. 
(C) The Se-DNA derivatized with the 6-Se-deoxyguanosine.  
 
We have found that selenium modification could help facilitate crystal growth significantly, 
as well as rationally solving phase problem in nucleic acid X-ray crystallography, where 
crystallization and phase determination are the two major challenges as we discussed before. Our 
previous studies on selenium modified nucleic acid X-ray crystallography illustrate that the 
selenium modification facilitates the crystal growth generally16-23, while there were no significant 
structure perturbations determined24-25. It also offers a novel method for the structure determination 
of the protein-nucleic acid complex, which helped to study the relationship between structure and 
function of enzymes such as RNase-H (Figure 1.3)26-27. What’s more, our previous study has 
revealed that the 2’-methylseleno modification can facilitate the crystallization of A-form DNA 
by destabilizing the B-form helix. The reason is the large methyl selenyl group cannot tolerate a 
B-helix geometry due to the steric hindrance with neighboring residues, but it fits well in the minor 
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groove of the A-form helix, which helps the transformation from B-form to A-form and further 
facilitates the crystallization (Figure 1.4)28. 
 
Figure 1.4 The 2’-SeCH3 group implanted in A and B helical structures 
 
1.3 Functional Study of Selenium Substitution on Nucleic Acids 
The study of Se-derivatized nucleic acids was started since 2001 and many different kinds 
of Se-modifications were introduced to DNA and RNA for structural and functional studies. 
Currently, selenium can almost be introduced at any position in nucleic acids replacing the oxygen 
atoms or inserting to different places on nucleotides, including sugar moiety, phosphate groups, 
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and nucleobases. Some examples of each kind of modifications will be introduced to discuss the 
influences and functions of selenium substitution on nucleic acids.  
 
1.3.1 Se-modifications on sugar moiety 
Among all the sites in nucleic acids for selenium derivatization, ribose 2’-position is the 
most widely explored. This Se-modification could facilitate crystal growth16-19, 21-23. Through 
collaboration among Huang, Egli and other co-workers, first crystal structure of nucleic acids was 
solved using direct selenium derivatization and MAD phasing (Figure 1.5A)25. After that, Micura 
and co-workers have developed the 2’-Se-RNA synthesis and made it possible to synthesize a Se-
RNA with up to 100 nucleotides via chemical synthesis and T4 RNA ligase ligation20, 29-30. As a 
successful application of 2’-Se-derivatized nucleic acid, a ligated 49 nucleotides ribozyme with 6 
selenium atoms modification was crystallized, and the structure was solved in approximately 3 Å 
resolution (Figure 1.5B) using MAD phasing31. This work provided new insights into the 
ribozyme catalytic pocket, substrate recognition, and catalytic mechanism of stereoselective 
carbon-carbon bond formation. Moreover, Ennifar and co-workers crystallized and solved some 
structures of complexes of HIV-1 genomic RNA dimerization initiation site (DIS) and antibiotics 
with 2’-Se-derivatization technique at 1.5 Å to 2.0 Å resolutions (Figure 1.5C)32. The great quality 
of the electron density maps of these structures revealed many details of drug–RNA interactions 
and offered important information for HIV-1 drug discovery.  
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Figure 1.5 The DNA and RNA structures with 2'-Se-modification. 
(A) 2’-Se-dU DNA octamer [5’-G(Se-dU)GTACAC-3’]2, PDB ID: 1Z7I. The red spheres 
represent the selenium atoms.  
(B) Structure of Diels–Alder ribozyme derivatized with the 2’-Se-functionality (PDB ID:1YLS). 
The red and yellow spheres represent the selenium atoms of 2’-Se-U (red) and 2’-Se-C (yellow). 
The compound in purple is the reaction product.  
(C) Structure of neomycin bound to HIV-1 genomic RNA dimerization initiation site (DIS) duplex 
with 2’-methylseleno derivatization. The red balls represent the selenium atoms. Neomycin 
molecules are in green dots (PDB ID: 3C7R). 
 
When compared with the native structure, both the structures of 2’-Se-DNA and 2’-Se-
RNA have well proven that this site-specific 2’-Se-modification does not significantly alter the 
global and local structures of nucleic acids. The detailed structural and hydration studies in A-form 
DNAs indicated that the selenium derivatization strategy has better structural isomorphism than 
the conventional bromine derivatization. Another exciting fact is that this kind of selenium 
modification at the 2’-position can significantly facilitate the crystal growth and broaden the 
crystallization buffer conditions for nucleic acids16-19, 21-23. The best explanation for this 
phenomenon is that 2’-selenium modifications could lock the sugar pucker and result in better 
molecular packing. 
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Besides 2’-Se-modifications, other modifications, including 4’-Se-modifications33 and 5’-
Se-modification34, were also reported. Each of these modifications has their specific conformation 
and potential applications. 
 
1.3.2 Selenium replacement of the phosphate non-bridging oxygen 
Egli and co-workers synthesized DNAs with selenium at the phosphate non-bridging 
position for the crystal structure study24. DNA phosphoroselenoates (PSe-DNA) were stable for 
months under the crystallization conditions. As expected, Se-modified structures are virtually 
identical with native (Figure 1.6A). In addition, the Mg2+ ion coordination is all the same in the 
Se-modified and native DNA structure. It is also worthy to mention that the PSe-DNA synthesized 
from solid-phase synthesis was a mixture of R and S diastereomers owing to the presence of the 
phosphorous chiral center. These diastereomers need to be separated by anion exchange 
chromatography24. In order to obtain diastereomerically pure PSe-oligonucleotide without the 
chromatography separation, our group developed enzymatic methods to synthesize the PSe-DNAs 
and PSe-RNAs by the enzymatic polymerization using the diastereomerically pure nucleoside 5’-
(α-P-seleno)-triphosphates35-37. Klenow DNA polymerase is able to recognize both dNTPαSe 
diastereomers35, while T7 RNA polymerase specifically recognizes only one NTPαSe 
diastereomer out of each NTPαSe diastereomer pair36. This Se-derivatization strategy on the 
backbone has been applied to solve some structures that could be extremely difficult for native 
sequences. The structure of a homo-DNA [d(CGAATTCG)2] (Figure 1.6B and C)
38 could be a 
good example of PSe-DNAs. From this crystal structure, more detailed information about the 
homo-DNA, especially the role of the backbone-base inclination and the inter-strand stacking in 
pairing selectivity, was revealed. 
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Figure 1.6 Structures of the phosphoroselenoate DNAs (PSe-DNA). 
(A) Superimposition of the PSe-DNA (in blue; PDB: 1VRO) and the native DNA with the same 
sequence [d(CGCGCG)2, in cyan; PDB: 2DCG]. The selenium atoms are shown as the yellow 
spheres in the PSe-DNA.  
(B) Crystal structure (PDB ID: 2H9S) of a homo-DNA [d(CGAATTCG)2]. Yellow spheres 
indicate the locations of the selenium atoms in the Home-DNA used for MAD phasing.  
(C) Chemical structure of the homo-DNA fragment. 
 
1.3.3 Selenium modification on the nucleobases 
Our group also led the investigation into the atom-specific modifications with selenium on 
the nucleobases. The previous research provides novel insights into the base pairing and stacking 
interactions of nucleic acids. Many different building block phosphoramidites of the 4-Se-T22, 6-
Se-dG39, 2-Se-T16 and 5-SeMe-T18 nucleosides for solid-phase synthesis and the 4-Se-T 
triphosphate for enzymatic synthesis40 have been developed and synthesized successfully.  
The 4-Se-T was introduced into a self-complementary octamer DNA [5’-G(2’-Se-dU)G(4-
Se-T)ACAC-3’, Figure 1.7A] for the structure study22. The crystal structure study indicated that 
this 4-Se-T modification can shift to accommodate a larger atom, such as selenium, in order to 
keep the excellent isomorphism in the overall structure with maintaining the similar base-pairing 
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and duplex stability. These structural data are consistent with the UV-melting study. The selenium-
mediated hydrogen bond was observed in this structure with a bond length of 3.35 Å (Se∙∙∙H–N), 
which is the first one demonstrated in a biological system. In addition, the 4-Se-T 5’-triphosphate 
was synthesized and effectively incorporated into DNA oligonucleotides with the catalysis of 
Klenow fragment of DNA polymerase I40. 
 
Figure 1.7 Crystal structures of the Se-nucleobase-modified oligonucleotides. 
(A) The 4-Se-T-modified DNA octamer [5’-G(2’-Se-dU)G(4-Se-T)-ACAC-3’]2, PDB ID: 2NSK.  
(B) The 2-Se-T-modified DNA octamer [5’-G(2’-Se-dU)G(2-Se-T)ACAC-3’]2, PDB ID: 3HGD. 
The red balls represent the selenium atoms on the nucleobases, and the yellow balls represent the 
2’-Se atoms. The 2’-Se-functionality was incorporated in the sequences to facilitate crystallization. 
(C) The 6-Se-G-DNA/RNA hybrid duplex (5’-AT(6-SeG)TC(6-SeG)-p-3’/5’-UCGACA-3’), 
PDB ID: 2R7Y. 
 
The oxygen at the 2-position of thymidine has also been successfully replaced by selenium 
in our lab (Figure 1.7B)16. Besides the application in crystallography, this 2-Se-T residue has also 
been tested to probe base pair specificity since the 2-position of T is involved in the T-G wobble 
pair. Watson–Crick base pairs are the contributors to the sequence-dependent recognition of 
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nucleic acids, genetic information storage, as well as the high fidelity of DNA polymerase 
replication and RNA polymerase transcription. However, the wobble base pairing, where T (or U) 
pairs with G instead of A, is commonly observed in duplexes, especially RNA duplexes, which 
reduces base-pairing recognition specificity and decreases the high fidelity of enzymatic 
polymerization. The T-G wobble pairing (or U-G) is caused by the shift of hydrogen bonding 
between the 2-exo-oxygen on T (or U) and 1-nitrogen on G in the base pairs, while the 2-exo-
oxygen atom is not involved in T-A (or U-A) base-pairing. The 2-position is critical for the 
discrimination of T-A vs. T-G pairs (or U-A vs. U-G). Therefore, we hypothesized that the 
introduction of a selenium atom at the 2-position can largely increase the electronic and steric 
effects, resulting in strong discrimination between normal T-A pairing and T-G wobble pairing. 
To investigate nucleic acid base-pairing fidelity and stacking through the atom-specific 
mutagenesis and crystallography, we synthesized 2-Se-thymidine phosphoramidite and 
incorporated it into DNAs via solid phase synthesis. The biophysical results supported our 
hypothesis and indicated that the 2-Se-T-substitution largely increased the T-A base pair fidelity 
by discouraging the T-G and T-C mispairs. The crystallographic study further revealed that this 
selenium-atomic substitution did not significantly change the native T-A base pairing and the 
overall structure. Thus, this atom-specific selenium substitution of the 2-oxygen of thymidine 
provides a unique chemical strategy to enhance the base pairing specificity.  
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Figure 1.8 Structure of RNase H/Se-DNA/RNA complex with 6-Se-G modification. 
(A) Left: The Se-DNA/RNA-RNase H structure (PDB ID: 3TWH); Right: The native DNA/RNA-
RNase H structure (PDB ID: 2G8U); 
(B) Superimposed Native (in gray) and Se-modified (in color) complex cleavage-site interactions; 
(C) Local subtle unwinding of the Se-modified duplex. 
 
Similarly, the 6-Se-dG was incorporated into DNAs (Figure 1.7C), and the crystal 
structure study of the DNA [5’-AT(6-Se-dG)TC(6-Se-dG)-p-3’] was carried out using a ternary 
complex of the 6-Se-dG-DNA/RNA/RNase H27. The structure was reported with the resolution of 
1.80 Å (PDB ID: 3TWH). A subtle conformation change was observed based on this high-
resolution structure. Comparing to the corresponding native complex with the same sequence 
(PDB ID: 2G8U), RNase H recognizes the internal position, instead of binding to the junction of 
the Se-modified DNA/RNA duplex. This result leads to the formation of the substrate-RNase H 
complex (Figure 1.8A). This Se-modified DNA/RNA/RNase H complex was also compared with 
another native RNase H complex (PDB ID: 1ZBI) which containing a longer substrate sequence. 
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The Se-dG3/rC5 base pair shows a conformation change by 0.5-0.7 Å which unwinding the duplex 
and slightly shift the scissile phosphate closer to the RNase H active site by approximately 0.3 Å 
(Figure 1.8C). What’s more, the scissile phosphate also positions the water nucleophile in the 
structure by forming a hydrogen bond (3.10 Å) (Figure 1.8B). Further RNA hydrolysis study 
shows that, in the presence of Se-DNA guide, the rate of hydrolysis is about 62-fold faster, which 
suggests that this subtle conformation change introduced by Se-modification significantly 
accelerating the RNA cleavage. 
 
1.4 Potential in clinical therapeutic and drug development 
Compared to protein, nucleic acid attracted much less attention as drug targets in the 
structure-based drug design, partially because of the lack of structural information of nucleic acids 
with drug candidates. By facilitating the crystallization and improving crystal quality, Se-modified 
nucleic acids can greatly promote the structure-based drug design of nucleic acids. Those detailed 
3D structures can help the researcher understand the structure of drug target or even the 
interactions between the targets and small molecule ligands. 
Moreover, oligonucleotides itself has been studied for over 30 years as potential 
therapeutics. The major oligonucleotides therapeutics containing antisense oligonucleotides, 
aptamers, ribozymes, and siRNAs, were studied extensively and lots of progress has been achieved. 
However, until 2017, there are only six drugs approved by FDA13. Many obstacles slow down the 
development of DNA/RNA-based therapies including the vulnerability to nucleases, off-target 
effects, poor delivery and low affinity. Lots of chemical modifications of nucleic acids were 
developed to conquer those challenges such as phosphorothioate (PS), 2’-O-methyl (2’-OMe), 
locked nucleic acids (LNAs), phosphorodiamidate morpholino oligomer (PMO) and so on41, which 
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can increase affinity, nuclease resistance, delivery, and reduce off-target effects by altering the 
structure and charge of the oligonucleotides.  
The previous study on Se-modified nucleic acid shows that replacement of the non-
bridging oxygen of DNA and RNA backbone phosphates protect the oligonucleotide from 
degradation by nucleases35, 37. Thus, the Se-modified siRNA may have improved RNase resistance, 
suggesting a potential therapeutic application on RNAi. Moreover, certain modifications, such as 
2’-MeSe, reduce multiple conformations of nucleic acid by destabilizing other unfavorable 
structure28 which can potentially increase the affinity and specificity of DNA/RNA duplex by 
reducing the entropic penalty. The consequent longer half-life allowing effect delivery to tissues 
of interest. Furthermore, the anticancer activity of selenium-modified nucleotides was also 
reported42. 
Overall, Se-derivatized nucleic acids (SeNA) possess many unique properties and show 
great potential in clinical therapeutic as well as drug development. However, the studies on SeNA 
are still limited and the synthesis is relatively costly, which may prevent broader applications. We 
expect that further progress and applications of SeNA will be achieved in the future. 
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2 SELECTIVE GENE SILENCING WITH SE-MODIFIED ANTISENSE DNA 
2.1 Introduction 
2.1.1 Challenges in antisense therapy 
In 1978, Zamecnik and Stephenson reported that an oligonucleotide complementary to the 
Rous sarcoma virus could block viral replication in chicken fibroblasts.43 This discovery opened a 
new world of antisense oligonucleotides. An antisense DNA is a single-strand DNA that is 17-22 
nucleotides in length and complementary to a selected gene’s mRNA and thereby specifically 
inhibit expression of that gene.  
There are two different strategies of antisense therapeutic, arresting and RNase H cleavage 
(Figure 2.1). Modified antisense DNA could bind to target mRNA through Watson-Crick base 
pairs. Formation of the RNA/DNA duplex may exert a direct steric effect, blocking the binding of 
factors required for the initiation of translation or impeding translocation of the ribosome along 
the mRNA resulting in chain-termination. In this way, the translation was arrested, and the target 
gene could be downregulated or even silenced. Alternatively, the mRNA may be cleaved by RNase 
H at the site of the RNA/DNA hybrid. RNase H is a kind of non-sequence-specific endonuclease 
enzyme that catalyzes the cleavage of RNA on RNA/DNA hybrid. When mRNA was cleaved, 
antisense DNA will be released and is able to bind to another mRNA and introduce the RNase H 
cleavage on that mRNA as well. It is obvious that the better strategy is the one involved RNase H 
because less antisense DNA is needed to have the same effect. 
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Figure 2.1 Two strategies of antisense therapeutic. 
(A) Arresting strategy44; (B) RNase H cleavage strategy. 
 
In general, there are several major challenges in DNA antisense strategy: RNase H 
compatibility, thermo-stability, nuclease resistance, and delivery. Due to its natural compatibility 
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with RNase H, unmodified native DNA could efficiently assist the enzymatic RNA cleavage. 
However, it was quickly discovered that unmodified DNA is unstable against nucleases. To 
enhance the nuclease stability and duplex affinity, the enormous number of DNA chemical 
modifications, mainly on the backbone and sugar, have been synthesized and applied in antisense 
strategy, mainly via the mRNA-arresting mechanism. However, heavy modifications may solve 
the problem of nuclease instability, but they can create some other problems like losing target and 
RNase H incompatibility. The losing target problem is usually caused by a weaker ability to form 
stable Watson-Crick base pairs. And the RNase H incompatibility is probably caused by disrupting 
the natural dynamics of the sugar pucker and backbone and interrupting the necessary interactions. 
Though gene silencing without RNase H activity can still be achieved via the mRNA-arresting 
mechanism, the catalytic power of RNase H in RNA inactivation is not harnessed. This is a 
significant loss in gene silencing efficiency. 
 
2.1.2 Current modification of antisense DNA 
Currently, the chemical modification is one of the effective strategies to optimize antisense 
therapies. In the past decades, numerous efforts have been devoted to achieving chemically 
modified nucleic acid drug molecules, which improve the nucleic acids properties tremendously 
in vivo. Since the first oligonucleotide drug, Fomivirsen, got approved by FDA in 199845, there 
are several oligonucleotide drugs have been approved by FDA13. And early this year 2018 in 
August, Patisiran became the first FDA approved siRNA drug46. All of these oligonucleotide drugs 
have one or several different kinds of modifications to stabilize them and avoid hydrolysis by 
nucleases. These modifications involve all three types of internucleoside linkage or backbone 
modifications, sugar modifications and nucleobase modifications41.  
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Figure 2.2 Some modifications that exist in FDA approved antisense drugs. 
(A) Phosphorothioate; (B) 2’-O-Alkyl; (C) LNA; (D) 5-methyl-C. 
 
2.1.2.1 Internucleoside linkage or backbone modifications 
These kind modifications are also referred to as the first generation of chemically modified 
antisense agents, including phosphorothioate, methylphosphonate, N-3’-phosphoramidate and 
many other modifications.  
Among them, phosphorothioate oligonucleotides are the most successful in gene silencing 
(Figure 2.2A). Among the FDA approved drugs, Fomivirsen, Mipomersen, and Nusinersen 
involve this kind of modification. Introducing phosphorothioate linkage to oligonucleotides could 
significantly increase the resistance to nuclease degradation. In addition, phosphorothioate 
oligonucleotides could also permit RNase H, form regular Watson-Crick base pairs, carry negative 
charges for cell delivery as compared to natural phosphodiesters47-49. However, their binding 
affinity to target mRNA sequences and specificity are less satisfactory50. Despite the disadvantages, 
phosphorothioate oligonucleotides are the most widely used and successful modification for 
oligonucleotide drugs. 
21 
 
2.1.2.2 Sugar modifications 
In recent years, there are great progress in the synthesis of conformationally constrained 
nucleoside analogues by modifying the sugar moiety in various ways. These modifications include 
synthesis of nucleoside analogs containing an electronegative atom or substituent at the 2’-position 
of sugar51-52, synthesis of bicyclic nucleoside analogs having an extra ring fused to the sugar 
moiety53-58 and some other methods. 2’-O-Methyl (2’-OMe) (Figure 2.2B) is a good example for 
the former while locked nucleic acid (LNA) (Figure 2.2C) is a widely used example for the latter. 
These secondary generation oligonucleotides could solve some problem of poor binding affinity 
to the target RNA, lack of specificity and low cellular uptake that phosphorothioate could have.  
The major structural difference between DNA and RNA is RNA has a 2’-OH group on 
sugar ring, which leads to C3’-endo conformation. The RNA binding affinity of antisense 
oligonucleotides could be improved by mimicking RNA structures with 2’-modified nucleosides. 
Electronegative substituents like fluorine and oxygen influence the furanose sugar C3’-endo 
conformation59 and make it easier to form A-type duplexes with target RNA strand52. Various 
reported 2’-substitutions have shown excellent results in antisense therapeutics as they provide 
high metabolic stability and high affinity to target the complementary mRNA, such as 2’-OMe and 
LNA. Mipomersen and Nusinersen are good examples of FDA approved drugs which contain this 
kind of modifications. 
 
2.1.2.3 Nucleobase modifications 
Normally most scientists modify the nucleobases to increase the binding affinity of 
oligonucleotides instead of nuclease resistance because nucleobases provide the prime recognition 
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site for Watson–Crick base pairs60. Thus, nucleobase modifications are less popular than those 
backbone and sugar modifications. However, some kinds of modifications also have great 
applications in antisense oligonucleotide drugs. The most attractive sites for substitution of the 
nucleoside bases are those positions in the major grooves because modifications on these positions 
neither interfere with base pairing nor induce steric hindrance and influence the general geometry 
of the double helix61-63.  
The stacking interactions between the planar heterocycles of nucleic acids are largely 
responsible for the stability of DNA and RNA duplexes. Maximizing stacking interactions through 
chemical modification provides a means of creating duplex helices of greater stability. However, 
so far there are no FDA drugs with modifications in this way, despite the fact that Mipomersen 
and Nusinersen have 5-methyl-C modifications (Figure 2.2D).  
 
2.1.3 The advancement of selenium modifications for antisense drugs 
As we discussed before, even though a lot of various modification methods have been 
developed, none of them can solve all the problems. The basic conflict is that atom specific 
modifications may not be able to confer sufficient resistance to nucleases or decrease the 
specificity and binding affinity, while heavy modifications could lead to loss of RNase H 
compatibility.  
However, we think selenium atom specific modification could be a solution that can solve 
all those problems. First of all, selenium is a kind of essential micronutrients in the human body, 
so it has low toxicity. And We spent many years on Se-modified nucleic acids research and made 
a lot of progress in the past 15 years. We found that selenium substitution of the non-bridging 
oxygen of DNA and RNA backbone phosphates protect the oligonucleotide from degradation by 
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nucleases35, 37. On the other hand, the 2-Se-T modification could significantly increase the 
specificity and binding affinity of Watson-Crick base pairs and avoid wobble pairs64-65. What’s 
more, the most exciting result is that we found 6-Se-dG modified oligonucleotides could not only 
maintain but even increase the RNase H activity27.  
Although these modifications are at different positions, we believe Se-modified nucleic 
acids have the potential to become a novel successful antisense oligonucleotide drug. We would 
like to further study whether there is a possibility to find a single atom specific selenium substituted 
modification that could solve all the problems that we mentioned before. In this way, we 
synthesized 5-methylselenium-thymidine (Figure 2.3). 5-methylselenium-thymidine contains a 
selenium atom at 5 position on the pyrimidine ring on thymidine. The 5 position does not involve 
in base pair formation, so we predict this modification will not affect the ability forming stable 
base pairs with adenosine on target mRNA. And the modification is in the major groove while 
when RNase H is binding to the minor groove of DNA/RNA duplex. Therefore, we believe this 
modification will not lose the compatibility with RNase H. However, we believe base 
modifications can also stabilize the antisense from nucleases. To prove our hypothesis, we insert 
it to oligonucleotides to investigate how it performs as antisense oligonucleotide and whether it 
has therapeutic potential as an antisense drug. 
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Figure 2.3 Structure of 5-methyselenium-thymidine. 
 
2.2 Material and Methods 
2.2.1 Se-modified antisense DNA resistance to serum 
Kinase reaction for DNA substrate: Set up 20 μL reaction with DNA substrate (2 μL, 50 
μM), T4 polynucleotide kinase (1 μL, Biolab), [γ-32P]-ATP (1 μL, PerkinElmer) and 10× kinase 
reaction buffer (2 μL, Biolab) at 37 °C for 1 h. Stop the reaction by adding high concentration 
NaCl (1 μL, 3M). Add ethanol (11 μL) and keep at -20 °C for 15 min. Centrifuging at 14,800 rpm 
for 20 min. Remove the supernatant carefully. Let it dry and redissolve the labeled DNA in water 
(10 μL). 
Digestion of labeled DNA substrate by Serum: Set up 5 μL reaction with labeled DNA 
substrate (1 μL, 5 μM), and Fetal Bovine Serum (final 4% v/v, Thermofisher) at 37 °C. Stop the 
reaction by adding dye (10 μL). 
Polyacrylamide gel electrophoresis (PAGE) detection: Prepare 19% polyacryl-amide 
gel (16.8 g urea dissolve in 20 mL 40% acrylamide and 8 mL 5× TBE buffer, add 100 μL 10% 
APS and 20 μL TEMED). Load samples and start electrophoresis in 1× TBE buffer (21.6 g Tris 
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base, 11 g Boric Acid, 1.5 g EDTA add water to 2 L and adjust pH to 8.3) at 800 V for 1 h. Place 
the gel on dryer for 2 h. Expose on film for 1 h and develop. Gel image was quantified by 
ImageQuant TL software. 
 
2.2.2 RNase H activity with Se-modified antisense DNA 
2.2.2.1 RNase H expression and purification 
Transformation of RNase H plasmid to BL21: Place human RNase H plasmids (From 
Dr. Wei Yang’s lab) and competent BL21 cell on ice bath. Add plasmid (1 μL, 200 ng/μL) to the 
competent cell and keep on ice bath for 30 min. Keep it at 42 °C water bath for 90 s. Then put it 
back on ice bath for 3 min. Add S.O.C medium (200 μL, Invitrogen) and shake at 37 °C 225 rpm 
for 45 min. Then pour 100 μL culture to the LB plate with 100 μg/mL ampicillin. Incubate at 37 °C 
overnight. 
Expression of RNase H: Pick single colony from the LB plate into 30 mL autoclaved LB 
broth with 100 μg/mL ampicillin. Shake at 37 °C 225 rpm overnight. Then add 10 mL overnight 
incubated BL21 to each litter of 2×1 L LB broth with 100 μg/mL ampicillin and shake at 37 °C 
225 rpm for 3 h. Add IPTG (1 mL, 1 mol /L) to each litter of the broth to induce the expression of 
RNase H and continue shaking overnight at 20 °C. Harvest the cell by centrifuging at 4 °C 5,000 
rpm for 30 min. Keep the precipitation at -80 °C. Dissolve the cell in His-tag column buffer A (20 
mM Tris pH 7.4, 1 M NaCl, 10 mM Imidazole, 5% Glycerol). Sonicate the cells with 60 × 15 s 
bursts. After each 15 s sonication wait 20 s to let the suspension cool down. Centrifuge at 4 °C 
10,000 rpm for 30 min. Keep the supernatant at -80 °C. 
Purification by His-tag column: Wash the column by buffer B (20 mM Tris-HCl pH 7.4, 
1 M NaCl, 300 mM Imidazole, 5% Glycerol) and followed by buffer A each for 5-column-volume. 
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Load sample. Wash the column by buffer A until the UV value is flat. Then wash the column by 
10% buffer B until the UV value almost go back to the low value. Elute sample by gradient from 
buffer A to buffer B (up to 100% in 60 min). Dialyze the protein against 2 L Phenyl column buffer 
B (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 5% Glycerol) overnight. Detect the concentration of 
sample by UV analysis. Use thrombin to cleavage His-tag by the concentration of 5 U/mg. Add 
same volume of buffer C [20 mM Tris-HCl pH 7.4, 100 mM NaCl, 4 M (NH4)2SO4, 5% Glycerol]. 
Purification by Phenyl column: Wash the Phenyl column by buffer B (20 mM Tris-HCl 
pH 7.4, 100 mM NaCl, 5% Glycerol) and then buffer A [20 mM Tris-HCl pH 7.4, 100 mM NaCl, 
2 M (NH4)2SO4, 5% Glycerol], each for 5-column-volume. Load sample. Wash the column by 
buffer A until the UV value is flat. Elute sample by program increased buffer B (up to 100% in 60 
min). Dialyze the protein against 2 L storage buffer (20 mM Tris-HCl pH 7.4, 2.8 mM β-
mercaptoethanol, 100 mM NaCl, 5% Glycerol) overnight. Concentrate the sample to 8 mg/mL (0.5 
mmol/L) and store the enzyme at -80 °C.  
SDS-PAGE: Prepare the gel-loading sample with protein sample (2 μL) in mixture of 
water (6 μL) and 5×loading buffer (2 μL, 250 mM Tris-HCl pH 6.8, 10% SDS, 0.02% 
bromophenol blue, 5% β-mercaptoethanol, 30% Glycerol). Load samples on 4%-20% SDS gel 
(Bio-rad) and start electrophoresis in 1 × Running buffer (3.02 g Tris base, 14.4 g glycine, 1 g 
SDS, add water to 1 L and adjust pH to 8.3) at 150 V for 40 min. Take out the gel and put in 
Coomassie Brilliant Blue Staining Solution (Bio-Rad) in microwave for 1 min. Then put in 
destaining buffer (10% ethanol and 10% acetic acid in water) and shake at 37 °C for 1 h. 
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2.2.2.2 RNase H reaction 
Digestion of biotin labeled RNA substrate by RNase H: Set up 10 μL reaction with 
biotin labeled RNA substrate (1 μL, 1 μM), DNA template (1 μL, 1 μM), 10× RNase H reaction 
buffer (1 μL, Biolab) and RNase H (1 μL, 100 nM) at 37 °C. Stop the reaction by adding dye (10 
μL). 
 
2.2.2.3 Biotin labeled RNA substrate detection 
Polyacrylamide gel electrophoresis (PAGE) and transfer membrane: Prepare 19% 
polyacrylamide gel (16.8 g urea dissolve in 20 mL 40% acrylamide and 8 mL 5× TBE buffer, add 
100 μL 10% APS and 20 μL TEMED). Load samples and start electrophoresis in 1× TBE buffer 
(21.6 g Tris base, 11 g Boric Acid, 1.5 g EDTA add water to 2 L and adjust pH to 8.3) at 150 V 
for 1 h. Soak the biodyne B nylon membrane (Thermofisher), gel and filter papers in 1× TBE 
buffer. Assemble the transfer sandwich and make sure no air inside. Transfer with Bio-rad Trans-
Blot Turbo at 1.3 mA for 7 min. 
Incubation and imaging: Block the membrane with warmed blocking buffer (20 mL, 
Thermofisher) for 30 min. Prepare conjugate/blocking buffer solution by adding the stabilized 
streptavidin-horseradish peroxidase conjugate (70 μL) to warmed blocking buffer (20 mL, 
Thermofisher). Incubate the membrane in conjugate/blocking buffer for 20 min. Wash membrane 
four times for 5 minutes each in 1× wash solution (20 mL) with gentle shaking. Incubate membrane 
in substrate equilibration buffer (30 mL) for 5 minutes with gentle shaking. Prepare 
chemiluminescent substrate working solution by adding luminol/ enhancer solution (6 mL, 
Thermofisher) to stable peroxide solution (6 mL, Thermofisher). Pour the substrate working 
solution onto the membrane and incubate membrane in the substrate solution for 3 minutes. 
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Remove and wrap the moist membrane in plastic wrap. Place the membrane in a film cassette and 
expose to film. Develop the film. Gel image was quantified by ImageQuant TL software. 
 
2.2.2.4 UV-thermal denaturation 
UV-thermal denaturation: The thermal denaturation experiments were performed on a 
Varian CARY-300 spectrophotometer equipped with a Peltier thermoprogrammer for data 
collection and analysis. Stoppered quartz cuvettes of 10 mm optical path length and 1 ml volume 
were used for the measurements. The cell holder was thermostatted with circulating water. The 
DNA/RNA samples were prepared by diluting to 4 μM each strand in buffer (350 mM NaCl, 10 
mM sodium phosphate pH 7.0, 0.1 mM EDTA) and then annealing by heating up to 90 °C for 2 
min and then slowly cool down to 4 °C. The temperature dependence of the absorption value of 
the DNA was monitored at 260 nm. The temperature of the cell holder was increased from 4 °C to 
60 °C at a rate of 0.5 °C/min. A temperature probe, immersed directly in a control cuvette, 
measured the sample temperature. The thermal melting temperature (Tm) was determined from the 
peak of the computer-generated first derivative of the absorbance versus temperature profile.  
 
2.2.3 Structure study on DNA/RNA/RNase H complex 
Crystallization of DNA/RNA/RNase H complex: Prior to co-crystallization with RNase 
H, the purified native or Se-modified DNA (5'-ATGTCG-3') and RNA (5'-UCGACA-3') were 
annealed at 1:1 molar ratio by first heating the mixture to 90 °C for 1 min, and then allowing it to 
cool slowly down to 25 °C. The resulting DNA/RNA duplex was mixed with the protein (final 
concentration: 2 mg/mL) at 1:1 molar ratio in the presence of 2 mM MgCl2. Co-crystallization of 
Se-DNA/RNA hybrid with RNase H was achieved by screening with the QIAGEN Classics Suite 
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Kit (www.qiagen.com). By using the sitting-drop vapor diffusion method at 25 °C, the crystals 
were readily obtained from the mixture #96 of the crystallization screen [Buffer: 0.1 M MES, pH 
6.5; precipitant: 12% (w/v), PEG 20000]. 
Data collection and structure determination: Crystal diffraction data of the Se-
DNA/RNA/RNase H complex were collected at beamline 8.2.1 and 8.2.2 in the Advanced Light 
Source (ALS). 25% glycerol was used as cryoprotectant while X-ray data were collected under the 
liquid nitrogen stream at 100 °K. Crystal of Se-DNA/RNA/RNase H complex diffracted X-rays to 
1.80. The data were processed and scaled using HKL2000, and the structures were solved by 
molecular replacement using Phasing in CCP4i with Dr. Wei Yang solved structure (PDB# 2g8u) 
as model. The resulted model was refined using Refmac5 within CCP4i. The modified DNA was 
modeled into the structure using Coot. Metal ions and water molecules were added either 
automatically or manually using Coot. 
 
2.2.4 Cellular level gene silencing with Se-modified antisense DNA 
2.2.4.1 HeLa cell culture 
HeLa Cell Recovery: Take the cell out from liquid nitrogen and keep it in 37 °C water 
bath. Centrifuge cells for 4 min at 1,000 rpm as soon as the media melt. Remove the supernatant. 
Resuspend cells in about 1 mL media. Transfer the cells to a cell culture flask with about 10 mL 
media. Continue culture the cell in incubator and change the media in 24 h. 
HeLa cell passaging and splitting: Check cells in flask under microscope to confirm that 
the cells are 80% - 100% confluent. Use the aspirator, empty liquid media covering cells. Use PBS 
(5 mL, Thermofisher) to wash the cells for two times. Add trypsin (1 mL, Thermofisher) to flask 
and keep in incubator at 37 °C for about 3 min. Check cells in flask under microscope to confirm 
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that the cells are detached. Add DMEM media (5 mL, Thermofisher) to the cells and then transfer 
to a 15 mL tube. Centrifuge cells for 4 min at 1,000 rpm. Remove the supernatant. Cell pellet 
should remain at base of tube. Resuspend cells in about 10 mL and separate them to 3 or 4 flasks. 
Continue culture the cell in incubator.  
HeLa cell cryopreservation: Check cells in flask under microscope to confirm that the 
cells are 80% - 100% confluent. Use the aspirator, empty liquid media covering cells. Use PBS (5 
mL, Thermofisher) to wash the cells for two times. Add trypsin (1 mL, Thermofisher) to flask and 
keep in incubator at 37 °C for about 3 min. Check cells in flask under microscope to confirm that 
the cells are detached. Add DMEM media (5 mL, Thermofisher) to the cells and then transfer to a 
15 mL tube. Centrifuge cells for 4 min at 1,000 rpm. Remove the supernatant. Cell pellet should 
remain at base of tube. Resuspend cells in about 1 mL media with DMSO (100 μL). Transfer the 
cells to a 1.5 mL Eppendorf tube. Keep the cell at 4 °C for 30 min. Then move to -20 °C for 1 h. 
Keep the cells at -80 °C overnight. Finally keep the cells in liquid nitrogen. 
 
2.2.4.2 Transfection and fluorescence detection 
Transfection: Check cells in flask under microscope to confirm that the cells are 70% - 
90% confluent. Dilute enhanced green fluorescence protein (eGFP) plasmid (0.5 μL, 1 μg/μL) and 
antisense DNA (1 μL, 10 μM) in Opti-MEM medium (200 μL, Thermofisher). Dilute 
Lipofectamine Reagent (1.5 μL, Thermofisher) in Opti-MEM medium (200 μL, Thermofisher). 
Add diluted DNA to diluted Lipofectamine 2000 reagent and then incubate for 5 min at room 
temperature. Add DNA-lipid complex to cells. Detect the cells under fluorescence microscope 
after 24 h. 
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Fluorescence detection with plate reader: Grow cells on 12-well-plate. Allow cell to 
continue grow for 24 h or 48 h after transfection. Set excitation wavelength as 488 nm and emission 
wavelength as 509 nm. Fluorescence of the cell plates was quantified by plate reader. 
 
2.2.4.3 Western blotting 
Cell Collection: Use the aspirator, empty liquid media covering cells. Use PBS (5 mL, 
Thermofisher) to wash the cells for two times. Add trypsin (1 mL, Thermofisher) to flask and keep 
in incubator at 37 °C for about 3 min. Check cells in flask under microscope to confirm that the 
cells are detached. Add DMEM media (5 mL, Thermofisher) to the cells and then transfer to a 15 
mL tube. Centrifuge cells for 4 min at 1,000 rpm. Remove the supernatant. Cell pellet should 
remain at base of tube. Add Ripa Lysis buffer (200 μL, Thermofisher) and keep on ice for 30 min. 
Then centrifuge the samples for 30 min at 10,000 rpm. Add 5× loading buffer (40 μL, 2 μL, 250 
mM Tris-HCl pH 6.8, 10% SDS, 0.02% bromophenol blue, 5% β-mercaptoethanol, 30% Glycerol). 
Boil the sample at 100 °C for 5 min. 
SDS-PAGE: Load samples on 4%-20% SDS gel (Bio-rad) and start electrophoresis in 1× 
Running buffer (3.02 g Tris base, 14.4 g glycine, 1 g SDS, add water to 1 L and adjust pH to 8.3) 
at 150 V for 40 min. 
Transferring membrane: Prepare the PVDF membrane (Bio-rad) soaking in methanol 
for about 1 min. Soak the membrane, gel and papers in the transfer buffer. Assemble the transfer 
sandwich and make sure there is no air inside. Transfer with Bio-rad Trans-Blot Turbo at 1.3 mA 
for 7 min. 
Antibody incubation and imaging: Wash the membrane with TBST (20 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 0.1% Tween 20). Block the membrane with 5% milk in TBST at room 
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temperature for 1 h. Incubate the membrane with primary antibody overnight at 4 °C. Wash the 
membrane with TBST for 3 times. Incubate the membrane with secondary antibody at temperature 
for 1 h. Wash the membrane with TBST for 3 times. Then incubate the membrane with AP 
substrate for 3 min. Remove and wrap the moist membrane in plastic wrap. Place the membrane 
in a film cassette and expose to film. Develop the film. Gel image was quantified by ImageQuant 
TL software. 
 
2.3 Results and Discussion 
2.3.1 Se-modified antisense DNA resistance to serum 
Five DNAs shared the same sequence were used to test the resistance to serum. One of 
them is native and other four have 5-MeSe-T modified at different positions. Their sequences and 
MALDI-MS analysis information are shown in Table 2.1.  
 
Table 2.1 MALSI-TOF MASS analysis of 5-SeMe-T containing DNA for resistance test 
# DNA Sequence Calc. [M+H+]+ Observed 
2-1 5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’ 7352.9 7353.1 
2-2 5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’ 7432.8 7433.2 
2-3 5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’ 7432.8 7439.9 
2-4 5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’ 7432.8 7437.1 
2-5 5’- GTG CAC TGA TCA ATT AAT GTC GAC-3’ 7432.8 7438.3 
 
We set up the reactions with all five DNAs in 4% serum for 20 minutes and 60 minutes to 
compare their resistance to serum. The results are displayed in Figure 2.4. It is obvious that DNA 
2-5 has the best resistance among all the sequences. And from the statistical result, we can also 
find all modified DNA has a better resistance to serum compared with native DNA.  
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Figure 2.4 Resistance to serum of all five DNAs. 
(A) Gel image of all 5 DNA resistance test to serum for 20 and 60 minutes. 
(B) Statistical result of several repeats of the experiment. 
 
We have further compared the time course digestion curve of DNA 2-1 and 2-5 (shown in 
Figure 2.5). It is very interesting that native DNA 2-1 was digested immediately after mixed with 
serum and continuously digested until 60 minutes later when there was almost no full-length DNA 
remaining. On the other hand, DNA 2-5 was also digested when mixed with serum. However, after 
about 20 minutes digestion, the full-length DNA kept about 60% remaining and no longer digested. 
We think the DNases in the serum were able to bind to the Se-modified DNA, but it might have 
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difficulties to cleave the substrate and finish the reaction. That’s why the reaction rate was getting 
lower and lower and the full-length DNA finally kept about 60% remaining. Another possible 
explanation is that our modified antisense DNA make the RNase H enzyme lose its activity. No 
matter which is the reason that made this result happened, it proved that our 5-Se-T-modified DNA 
could increase the resistance against blood serum.  
 
 
Figure 2.5 Time course experiment of resistance to serum of DNA 1 and 5. 
(A) Gel image of time course serum resistance test for DNA 2-1 and 2-5. 
(B) Digestion curve of DNA 2-1 and 2-5 during the time course experiment. 
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2.3.2 RNase H activity with Se-modified antisense DNA 
RNase H is a kind of sequence non-specific nuclease that can digest the RNA when 
complementary DNA is hybridized, therefore, the RNase H mediated degradation of target mRNA 
is one of the basic mechanisms for antisense drug working. Some of the modifications in synthetic 
oligonucleotides could cause the loss of RNase H activity, probably due to the restriction in DNA 
backbone dynamic. Thus, although it was proved that our nucleobase modification could 
dramatically improve the stability against serum, whether it could still keep RNase H digestion on 
complementary mRNA is another concern. 
 
2.3.2.1 RNase H expression and purification 
RNase H (Bacillus halodurans) truncated (TR), and truncated mutant (D132N) constructs 
(pET 42 and pET13, respectively) were kindly given by Dr. Wei Yang lab at NIH as a gift. The 
truncated RNase H (59-196 aa) was created and retains the RNA hydrolytic activity on RNA/DNA 
duplex. Truncated inactive RNase H mutant was created, for crystal structure study, by mutating 
the aspartate residue (D132) of the truncated RNase H to asparagine (D132N). This mutation 
abolishes the metal ion coordination (B site) capability of the enzyme and makes the enzyme 
inactive catalytically. 
Protein expressions were carried out in BL21 (DE3; pLys E. coli; purchased from 
Invitrogen). Then after two columns purification, we obtained pure truncated RNase H. We kept 
the samples in each step of purification running PAGE gel as in Figure 2.6. 
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Figure 2.6 RNase H purification. 
1: Supernatant after cell lysis; 2: Purified by Ni column; 3: After thrombin digestion and buffer 
change; 4: Purified by phenyl column. 
 
2.3.2.2 Se-modified antisense DNA’s impact on RNase H cleavage 
We designed hexamer DNA and RNA for RNase H digestion test. Four DNAs shared the 
same sequence were used as DNA guide in RNase H cleavage. One of them is native, two have 
single modification on different positions while the last one is double modified on both positions. 
The sequence and MALDI-MS analysis information are in Table 2.2. 
 
Table 2.2 MALDI-TOF MASS analysis of DNA and RNA for digestion test 
# DNA Sequence Calc. [M+H+]+ Observed 
2-6 5’- ATG TCG-3’ 1808.3 1807.3 
2-7 5’- ATG TCG-3’ 1887.3 1886.5 
2-8 5’- ATG TCG-3’ 1887.3 1885.7 
2-9 5’- ATG TCG-3’ 1966.2 1965.2 
Biotin-RNA 5’-Biotin- UCG ACA-3’ - - 
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We set up reactions with RNase H, DNA template and biotin-labeled RNA substrate 
(purchased from Integrated DNA Technologies) and build up time course curve of RNA digestion 
with different DNA templates. The results are displayed in Figure 2.7.  
 
Figure 2.7 RNase H digestion curve of hexamer RNA binding to different DNA template. 
 
We surprised to find all the modified DNA guides keep the compatibility with RNase H 
and all of them make RNase H have even higher activity. We calculated the initial rate of the 
curves and found that all the modified DNAs lead to faster initial reaction rate and double modified 
DNA 2-9 has the highest value. This result indicates our Se-modified DNA has good RNase H 
compatibility and even makes RNase H has higher activity. 
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However, because the sequence for our DNA/RNA duplex is very short, most of them in 
solution at room temperature may not appear to be duplexes. Since RNase H can only bind to 
DNA/ RNA duplexes to cleavage the RNA strand, that could be a question that how the Se-
modification can improve the activity of RNase H. A possible explanation is that the Se-
modification may stabilize the duplex and increase the ratio of DNA/RNA duplexes in aqueous.  
However, the previous research based on 5-Se-T modified DNA duplexes does not support this 
result. It is reported that 5-Se-T modified DNA duplexes have almost the same Tm comparing with 
native DNA with the same sequence66. DNA/RNA duplex may have the different performance 
with DNA duplex, so we also measured the Tm for all four duplexes. The results are shown in 
Table 2.3. 
 
Table 2.3 Relative initail catalysis rate and Tm for different DNA/RNA duplexes 
DNA # DNA/RNA duplex sequences Tm 
2-6 
5’- ATG TCG-3’ / 5’- UCG ACA-
3’ 
13.5 ± 0.5 °C 
2-7 
5’- ATG TCG-3’ / 5’- UCG ACA-
3’ 
13.1 ± 0.7 °C 
2-8 
5’- ATG TCG-3’ / 5’- UCG ACA-
3’ 
13.2 ± 0.5 °C 
2-9 
5’- ATG TCG-3’ / 5’- UCG ACA-
3’ 
13.4 ± 0.4 °C 
 
It is obvious that Se-modifications do not make significant differences on the Tm of DNA/ 
RNA duplexes. So the thermos-stability of duplexes is not the critical reason of RNase H activity 
increase. We need to carry out a different explanation that why Se-modification can activate RNase 
H. In this way, we need to look in the structure of RNase H/DNA/RNA complex and try to draw 
out a better explanation on interactions between RNase H and DNA/RNA duplexes. 
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2.3.3 Structure study on RNase H/DNA/RNA complex 
We already proved that our modified DNA have almost the same or sometimes even better 
ability to work with RNase H and explained that the reason has nothing to do with the thermos-
stability. In order to understand how this happened through structural biology, we did crystal 
growth and X-ray structure determination to study how selenium affects the RNase H complex. 
The structure of Bacillus halodurans RNase H complexed with DNA/RNA duplex was well 
determined before by Dr. Wei Yang’s lab. Here we use the same sequences of DNAs and native 
RNA (5’-UCGACA-3’) for catalytic experiments (DNA sequence information is displayed in 
Table 2.2). 
 
2.3.3.1 Crystallization of RNase H/DNA/RNA complex 
We mixed 0.5 mM DNA and complimentary 0.5 mM RNA at 1:1 ratio. Then the 
DNA/RNA duplex was annealed by heating up to 80°C for 2 min, and slowly cooling down to 
room temperature. Then the duplex mixture was added to 3 mg/mL RNase H at 1:1 ratio in the 
presence of 2 mM MgCl2. Crystallization screening was performed with QIAGEN Classics Suite 
Kit with 0.2 μL sample and 0.2 μL crystallization buffer by sitting drop vapor diffusion method at 
25 °C. The crystals were readily obtained overnight from the mixture #96 of the crystallization 
screen [Buffer: 0.1 M MES, pH 6.5; precipitant: 12% (w/v), PEG 20000]. Then the crystallization 
was repeated manually with 1 μL sample and 1 μL crystallization buffer equilibrate against 500 
μL of 15% (v/v) MPD using hanging drop vapor diffusion method at 25 °C to get more crystals. 
The crystal was mounted, shock-frozen in liquid nitrogen with 25% glycerol as cryo-protectant. 
The crystals are displayed in Figure 2.8. 
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Figure 2.8 RNase H/DNA/RNA complex crystallization. 
(A) DNA 2-6; (B) DNA 2-7; (C) DNA 2-8; (D) DNA 2-9. 
 
2.3.3.2 Structure determination of RNase H/DNA/RNA complex 
The diffraction data of RNase H/DNA/RNA complex crystal was collected at beamline 
8.2.1 and 8.2.2 of the ALS (Advanced Light Source) at the Lawrence Berkeley National 
Laboratory. Several crystals were screened to find the crystal with the best diffraction quality. The 
diffraction data was collected at 1 Å wavelength for 1 second per frame with 1° oscillation angle. 
The best resolution for all 4 different DNA template was about 1.7 - 1.8 Å. The data were 
integrated and scaled by HKL2000.  
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Table 2.4 Data collection and refinement statistics of RNase H/DNA/RNA complex 
Complex structure 
RNase H/ RNA/ 
DNA 2-6 
RNase H/ RNA/ 
DNA 2-7 
RNase H/ RNA/ 
DNA 2-8 
RNase H/ RNA/ 
DNA 2-9 
Wavelength (Å) 1 
Resolution range 
(Å) 
50.0-1.70 
(1.76-1.70) 
50.0-1.80 
(1.86-1.80) 
50.0-1.80 
(1.79-1.73) 
50.0-1.70 
(1.76-1.70) 
Space group C2 
Unit-cell a, b, c (Å) 80.2, 37.6, 62.1 81.2, 37.7, 62.2 80.9, 37.6, 62.2 81.0, 37.8, 62.0 
α, β, γ (°) 90, 96.0, 90 90, 96.4, 90 90, 96.1, 90 90, 96.2, 90 
Unique reflections 18866 (1081) 17472 (1744) 19601 (1917) 20662 (2028) 
Completeness (%) 92.1 (53.7) 100 (100) 99.8 (99.5) 100 (100) 
Rmerge (%) 7.7 (23.5) 6.4 (40.8) 8.9 (22.5) 5.9 (41.4) 
I/σ(I) 21 (3.5) 29 (3.2) 54 (6.7) 31 (3.2) 
R value (%) 18.9 18.9 19.2 17.8 
Rfree (%) 23.4 21.8 23.4 22.1 
Average B value 
(Å2) 
15.6 24.4 27.8 22.1 
R.m.s.d. bond 
length (Å) 
0.019 0.020 0.021 0.021 
R.m.s.d. bond 
angle (°) 
1.85 1.98 2.04 2.13 
 
The structure of RNase H/DNA/RNA complex was solved by molecular replacement using 
Phaser in CCP4. The corresponding native structure obtained by Dr. Wei Yang’s lab (PDB entry 
2g8u; 2.70 Å resolution) with the same sequences was used as model67. The resulting model was 
refined using REFMAC in CCP4 and Coot. After several cycles of refinement, water molecules 
were added either automatically or manually using Coot. Data collection and structure refinement 
statistics are given in Table 2.5. Structure factor and final coordinate have been deposited in the 
Protein Data Bank (PDB ID: 5WJR, 5USA, 5USE, and 5USG).  
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2.3.3.3 Structure study of selenium atom impact on RNase H active center 
As shown in Figure 2.9A, the overall structure and binding site of RNase H/DNA/RNA 
complexes are all the same despite modification number and location. In this case, RNase H is 
binding to the gap of RNA where the red scissors are in Figure 2.9B. And all four structures are 
superimposed very well.  
 
Figure 2.9 Overall structure and binding site of RNase H/DNA/RNA complexes. 
(A) Overall structure of RNase H/DNA/RNA complexes. Complex with DNA 2-6 is green, DNA 
2-7 is yellow, DNA 2-8 is cyan, DNA 2-9 is red. 
(B) Binding site of RNase H/DNA/RNA complexes. 
 
We used RNase H complex with native RNA and DNA 2-9, which has most selenium 
modifications, as an example to illustrate why Se-modifications will keep the overall structure in 
Figure 2.10. We can find that the RNase H enzyme is binding to the minor groove of DNA/RNA 
duplex while selenium modifications are in the major groove because it is modified on 5 position 
of thymidine. We believe this is the reason why the RNase H complexes display consistency on 
the structure and RNase H enzyme keeps working with modified DNA templates. 
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Figure 2.10 RNase H complex structure with native RNA and DNA 2-9 
DNA strand is displayed in purple and RNA strand is displayed in cyan. 
Yellow spheres represent selenium atoms and red spheres represent magnesium ion. 
 
However, as we investigate the active center of RNase H, we can find some interesting 
results. Figure 2.11 display the structure of base pair at the active site of RNase H for all 4 
complexes. Because there is no phosphate group at the active center, we consider the distance 
between the magnesium ion and 3’-O on the sugar moiety of adenosine onsite as the most 
important value that how easy the reaction could happen. We believe the reaction is easier to 
happen when this distance is closer. We find if there is a modification on the deoxythymidine at 
the complementary place of adenosine onsite (DNA 2-7 and 2-9), the distance between magnesium 
ion and 3’-O on the sugar pucker of adenosine get closer. And this may be caused by changes on 
base pairs. We collected the related distance data and displayed those in Table 2.5. 
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Figure 2.11 Active site structure of RNase H/DNA/RNA complex. 
(A) DNA 2-6; (B) DNA 2-7; (C) DNA 2-8; (D) DNA 2-9. 
 
Table 2.5 Important Distance between in RNase H/DNA/RNA complex 
Distance (A) Between DNA 2-6 DNA 2-7 DNA 2-8 DNA 2-9 
Mg O3’/A6 2.56 2.39 2.49 2.37 
N3/T2 N1/A6 2.81 2.76 2.80 2.76 
O4/T2 N6/A6 2.91 3.04 2.95 3.02 
 
It seems that when there is a 5-Se-T on-site modification, the distance between N3 on dT 
and N1 on A get slightly closer, while the hydrogen bond between O4 on dT and N6 on A get 
longer. We think the large electron density of Se make the base pairs a little bit unwinding and 
push the Adenosine on RNA a little bit into the active core of RNase H and get closer to magnesium 
ion there. So in this way, the on-site modification could enhance RNase H activity. Off-site 
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modification may also have some indirect impact, and this is why DNA 2-8 also has a shorter 
distance between magnesium ion and 3’-O compare with DNA 2-6.  
As we accept this hypothesis, we can try to explain the result for RNase H activity research. 
Although we are using the same sequences of DNA and RNA in RNase H activity study and 
structure determination, the cleavage site and binding site in the crystal are different. In 
crystallization, the RNase H binds to the gap between two RNAs. However, if RNase H binds to 
the same place in catalysis, RNA could not be cleaved. Only when RNase H active center binds to 
the middle of the sequence and there are phosphodiester bonds existing, the cleavage could happen, 
and we can observe RNA is cleaved. By investing our previous published paper, we think the 
cleavage site on RNA is between A4 and C5 (displayed in Figure 2.12). In this way, DNA 2-8 and 
2-9 have the on-site modification while DNA 2-7 and 2-9 have the off-site modification. As we 
talked before, the on-site modification could lead to a significant increase in RNase H activity. 
This is constant with the catalysis results that DNA 2-9 has the highest RNase H activity and DNA 
2-8 comes later. 
 
 
Figure 2.12 Cleavage site of RNase H catalysis research. 
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2.3.4 Cellular level gene silencing with Se-modified antisense DNA 
It has been shown that our selenium modification has great potential as antisense drugs, 
due to both nuclease stability and RNase H compatibility. To investigate the gene silencing ability 
of this novel modified DNA targeting some specific gene in live cells, we performed the 
transfection experiment in HeLa cells using some CH3Se-containing DNAs. To visualize the gene 
silencing effect, we initially transfected the cells with the eGFP-containing plasmid. The plasmid 
was a generous gift from Professor Jenny Yang’s lab, GSU, and the green fluorescence protein 
gene was inserted in the pcDNA 3.1+ vector. The antisense oligonucleotide we chose was 18 
nucleotides long and targeted to the position 1496 of the eGFP gene. The sequence of antisense 
DNA was indicated in Table 2.6, and the CH3Se modification was labeled on those red T. 100 µM 
DNA solutions were prepared in water. The HeLa cells were grown in Dulbecco’ MEF containing 
10% heat-inactivated fetal bovine serum, 200 µg/mL glutamine, 100 u/mL penicillin, and 100 
µg/mL streptomycin at 37 °C, 5% CO2 in a moist atmosphere. 
 
Table 2.6 Sequence information of 5-SeMe-T DNA for cellular experiments 
# DNA Sequence 
2-10 5’-GAG CTG CAC GCT GCC GTC-3’ 
2-11 5’-GAG CTG CAC GCT GCC GTC-3’ 
2-12 5’-GAG CTG CAC GCT GCC GTC-3’ 
2-13 5’-GAG CTG CAC GCT GCC GTC-3’ 
2-14 5’-GAG CTG CAC GCT GCC GTC-3’ 
 
47 
2.3.4.1 Fluorescence determination results 
 
Figure 2.13 Cell images under fluorescence microscope. 
(A) Cell images under white light. 
(B) Cell images excited by blue light. 
(C) Statistic result of fluorescence intensity for all 5 DNAs by plate reader. 
(D) Statistic result of fluorescence intensity for different amount of DNA 2-10 and 2-14 by plate 
reader. 
 
Cells were seeded in 6-well plates 24 h prior to transfection at a density of 6 x 105 cells 
per well and incubated in 3 mL medium. For the transfection, the medium was exchanged with 
fresh medium. The eGFP gene-containing plasmid and antisense oligonucleotides were added 
simultaneously to the cells with lipofectamine 2000 reagent assisting and incubated for 24 h. After 
24 h incubation, the cells were visualized under Axiovert 200 fluorescence microscope excited by 
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blue light. The fluorescent intensity was measured by Plate Reader to have an idea about gene 
expression level. The results were demonstrated in Figure 2.13. Without transfecting plasmid, no 
eGPF was expressed at all (negative control). While without introduction of antisense 
oligonucleotides, the eGFP gene was actively expressed (positive control). When Cells were 
transfected with both eGFP plasmid and antisense DNAs, the gene expression was significantly 
suppressed. And Se-modified antisense DNA made the GFP expression even lower than with 
native antisense DNA. 
 
2.3.4.2 Western blotting results 
We performed Western Blot experiment to systematically quantify the different 
oligonucleotides’ gene silencing activity. After gene expression, HeLa cells were washed three 
times with phosphate saline buffer (PBS) and then scraped into 0.1 mL of RIPA lysis buffer 
containing the protease inhibitor. After incubation for 10 min on ice, the lysate was transferred to 
new tubes, followed by centrifuging at 14,000 g for 15 min at 4°C. After analyzing lysates by SDS-
PAGE gel, the analysis verified the downregulation of EGFP expression in cells treated with our 
antisense DNAs. Moreover, our Se-oligonucleotide has about 20% more gene silencing activity 
than the native one. Finally, the relative eGFP expression was calculated as the ratio of the 
fluorescence intensity on the control of beta-actin expression. Our quantitative result proved that 
DNA 4 and 5 with CH3Se-modifications, silenced the eGFP gene expression more effectively. The 
gel image and quantitative result are displayed in Figure 2.14. 
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Figure 2.14 Western blotting results. 
(A) Gel image for Western blotting. 
(B) Quantitative result for Western blotting. 
 
2.4 Conclusion 
The derivatization of DNA with selenium can give us a new strategy in the antisense drug 
application. The 5-Se-T modification on oligonucleotides provided better resistance to blood 
serum. A reasonable hypothesis is that the selenium atoms at 5-position has steric hindrance with 
some enzyme residue so that the protein structure slightly shifts and cleavage is inhibited. 
Moreover, even though the methyl selenyl group has an impact on nuclease catalysis, it maintains 
the RNase H activity when the modified DNA binds to complementary RNA because it does not 
cause significant structure changes. And for our case, the modified DNA even lead to higher initial 
catalysis rate of RNase H. We think this is because introducing selenium atom to on-site position 
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lead to base pair unwinding and the complementary RNA strand is pushed a little bit into the 
RNase H activity center. This generates an important pathway for antisense oligonucleotide 
working. The gene silencing experiments in HeLa cells also demonstrated that our novel modified 
antisense DNA has a brilliant prospective. We anticipate the nucleobase derivatization with 
selenium element can provide novel efficient chemical modification strategy in gene therapy 
design drug market. 
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3 SE-ANTISENSE DNA X-RAY FLUORESCENCE IMAGING 
3.1 Introduction 
Massager RNA (mRNA) is the center of the central dogma. It is the bridge between genetic 
DNA and functional protein. Translation is the process that ribosomes synthesize protein based on 
the information in mRNA. It is very important to understand where and how this process happens. 
Most scientists detect this process through newly generated fluorescence protein labeling68. 
However, during the translation process, we may not be able to visualize the protein before it is 
well folded and modified. When start visualizing the functional protein, it is already translated and 
well folded, however, it may not keep the same location where it was synthesized. If we can detect 
mRNA and protein at the same time, then we could judge that the place where the signal of mRNA 
and protein overlapped is the location that translation is taking place. In this way, not only to 
determine the protein but to visualize the localization and transportation of mRNA is very 
important to. 
Currently, most scientists are using fluorescent labeling for intracellular nucleic acids and 
oligonucleotides detection69-72. As a mains research method developed for decades, fluorescent 
labeling has many advantages. Since many of the fluorescent molecules with different excitation 
and emission wavelengths are developed73, it is possible for us to detect several different targets 
with different labeling at the same time. Real-time intracellular monitoring inside living cells is 
also accomplished with fluorescent labeling74-75. However, there are still some problems for 
nucleic acid detecting with fluorescent labeling. First of all, fluorescent labels are usually some 
small molecules attached to 5’ or 3’ of the nucleic acid73. These fluorescent molecules usually 
have aromatic rings, which may affect in base stacking and change the structure of nucleic acid. 
In this way, they may cause the off-target problem during the experiment. Quenching is another 
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possible problem, which will cause low intensity in long-term experiment76.  In addition, there 
may be also some other molecules that could generate fluorescence on the same excitation 
wavelength and cause high background77. 
Compared with normal fluorescence detection with small molecule labeling, micro-X-ray 
fluorescence (microXRF) detection with specific element could be more specific with higher 
intensity and lower background78-79. In this way, microXRF could be a better method for 
intracellular large biomolecule detection. Some metal ions have been used as the biosensor to 
detect intracellular biological processes involved different enzymes80-85. However, there is no 
effective sensor for nucleic acid so far. We developed Se-modified nucleic acids (SeNAs) for 
microXRF. SeNAs are single atom modification on nucleic acids. In our previous work SeNAs 
show the ability to remain the same structure and properties as native in many cases24-25. And most 
of the SeNAs are stable under normal experimental condition. Moreover, the intracellular Se 
concentration is very low86, so there could be almost no background for microXRF. All above 
conclude that SeNA could be an ideal method for intracellular specific nucleic acid study.  
In this way, we designed Se-modified antisense DNA with 5-Se-thymidine and the 
sequence targets to green fluorescence protein (GFP) mRNA. When we transfect this antisense 
DNA into the cell, it will bond to GFP mRNA (Figure 3.1). We can use microXRF to get the 
selenium signal which indicates where mRNA is. Meanwhile, we can also detect new generated 
GFP by fluorescence microscope at the same time. After comparing these two signals, we could 
tell where translation is taking place. 
 
53 
 
Figure 3.1 Processing of the experiment.  
After transcription, mRNA come out from nucleus to cytoplasm. Protein is synthesized on 
ribosome which binds to mRNA. This processing can be blocked by antisense DNA that has Se 
on it in our design. 
 
3.2 Material and Methods 
HeLa cell culture on microchips: Check cells in flask under microscope to confirm that 
the cells are 80% - 100% confluent. Use the aspirator, empty liquid media covering cells. Use PBS 
(5 mL, Thermofisher) to wash the cells for two times. Add trypsin (1 mL, Thermofisher) to flask 
and keep in incubator at 37 °C for about 3 min. Check cells in flask under microscope to confirm 
that the cells are detached. Add DMEM media (5 mL, Thermofisher) to the cells and then transfer 
to a 15 mL tube. Centrifuge cells for 4 min at 1,000 rpm. Remove the supernatant. Cell pellet 
should remain at base of tube. Resuspend cells in about DMEM media (10 mL, Thermofisher). 
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Place 4-5 microchips in each well of a 6-well plate. Place the resuspended cells in 6-well plates 
with microchips.  
HeLa cell transfection with microchips: Check cells in flask under microscope to 
confirm that the cells are 70% - 90% confluent. Dilute eGFP plasmid (2 μL, 100 ng/μL) and 
antisense DNA (0.5 μL, 10 μM) in Opti-MEM medium (200 μL, Thermofisher). Dilute 
Lipofectamine Reagent (0.6 μL, Thermofisher) in Opti-MEM medium (200 μL, Thermofisher). 
Add diluted DNA to diluted Lipofectamine 2000 reagent and then incubate for 5 min at room 
temperature. Add DNA-lipid complex to cells. Let the cells continue growing for 24 h. 
Cell Fixation: After 24 h, remove the medium. Wash cells twice with PBS buffer (200 μL 
each, Thermofisher) pre-warmed at 37 °C. Fix cells with 3.7% formaldehyde. Incubate at room 
temperature for 10 min. Remove 3.7% formaldehyde. Wash the cells with PBS (200 μL each, 
Thermofisher) for 3 times. Wash the cells 3 times with isotonic ammonium acetate (0.1 M, 200 
μL each) in sterile distilled water. Air-dried overnight, and then take out the chips from wells, store 
and ship. 
MicroXRF determination: We used XRF microprobe analysis to examine element 
distributions and concentrations in cells on microchips at beamline 2-ID-E of the Advanced Photon 
Source. An Si(III) single-bounce monochromator was used to tune the undulator synchrotron X-
ray beam to 12.9 keV. The beam was focused into a 0.5 μm spot using Fresnel zone plate optics. 
For element distribution maps, the sample was rastered through the focal spot with a step of 1-2 
μm and dwell time of 4 sec. A full energy-dispersive XRF spectrum was collected at each step 
using a Canberra three-element UltraLEGe detector (Canberra Instruments, Meriden, CT). 
Elemental maps were created by fitting the spectrum at each scan position with modified Gaussians 
using MAPS software (Vogt 2003). Area concentrations for elements were calculated by 
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comparing integrated intensities of fluorescence peaks with those from thin film standards (NBS 
1832 and 1833; National Bureau of Standards, Gaithersburg, MD). 
 
3.3 Results and Discussion 
3.3.1 Selenium aggregation of different DNA sequences 
Four different sequences of Se-modified DNA are used in the experiment and the 
sequences are displayed in Table 3.1. DNA 3-1 (perfect matched) is antisense DNA exactly target 
to GFP mRNA. DNA 3-2 is 4 bases mismatched and DNA 3-3 is 6 bases mismatched. DNA 3-4 
(control DNA) is a random sequence that is designed not to target any mRNA in HeLa cells. DNA 
3-1, 3-2 and 3-3 have 3 modifications on the sequences while DNA 3-4 have only 2 modifications. 
In order to make the selenium amount be the same level in cells, the DNA 3-4 was used to be 1.5-
fold concentration comparing to the other three sequences. We co-transfected the Se-DNAs with 
GFP plasmid to HeLa cells at the same time. The X-ray fluorescence microscope images for zinc 
and selenium of cell transfected with perfect matched DNA 3-1, mismatched DNA 3-2 and 3-3, as 
well as control DNA 3-4 are shown in Figure 3.2. There is a very low level of natural selenium in 
human cells, so the selenium background is close to zero. Selenium signal of perfect matched DNA 
is focus and appears as condensed spot. For mismatched DNA, we can also determine the 
condensed spot signal. However, the intensity of the signal is only about 50% comparing with the 
perfect matched group. And there is no condensed spot at all in those cells transfected with control 
DNA. 
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Table 3.1 Sequence information of 5-SeMe-T DNA for Imaging experiments 
DNA sensor DNA Sequence 
DNA 3-1 (perfect matched) 5'-GAG CTG CAC GCT GCC GTC-3' 
DNA 3-2 (4 bp mismatched) 5'-TAT CTG AAC TCT GCA GTA-3' 
DNA 3-3 (6 bp mismatched) 5'-TAT CTG AAC TCT GCA GTA-3' 
DNA 3-4 (control DNA) 5'-CTC CCA TCC-3' 
 
It is obvious that antisense DNA is going to bind and block GFP mRNA at certain area in 
the cells, so selenium aggregated at the certain places and appeared to be condensed spots in those 
cells transfected with perfect matched and mismatched Se-modified antisense DNA. What’s more, 
the cells transfected with mismatched DNA has weaker Se-aggregation phenomenon and the more 
bases mismatched, the weaker Se aggregated. We believe the reason for this is that mismatched 
DNA has a weaker ability to bind to the target mRNA. Meanwhile, control DNA do not bind to 
GFP mRNA at all, so it would be spread to everywhere inside and outside cells, which means no 
‘hot spots’ could be found in the images. In the way, the signal of Se also suggests where the target 
mRNA is.  
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Figure 3.2 Images of Se-oligonucleotides distribution in cells by X-ray fluorescence 
visualization. 
(A) DNA 3-1 is perfect matched with mRNA.  
(B) DNA 3-2 has 4 base pairs mismatched.  
(C) DNA 3-3 has 6 base pairs mismatched. 
(D) DNA 3-4 is control sequence. 
 
To compare the aggregation of Se more directly, we measured the strongest intensity of 
the signal in each picture and the average is displayed in Figure 3.3. The result agrees with our 
previous analysis that perfect matched DNA 3-1 has the highest average intensity, mismatched 
DNA 3-2 and 3-3 are weaker, and control sequence DNA 3-4 have the weakest signal and it is 
close to zero.  
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Figure 3.3 Average strongest intensity of Se for the pictures of each DNA. 
 
3.3.2 Certain mRNA distribution in cells 
We obtain even more images of Se and Zn for those cells transfected with DNA 1 and they 
are displayed in Figure 3.4. As we known, zinc is normally condensed in cell nucleus because of 
zinc figure structures87. We consider zinc signal as the location of the nucleus in the cell. Through 
the overlap pictures of zinc and selenium signal in Figure 3.2 and 3.4, we can conclude that Se-
antisense DNAs are outside the nucleus. 
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Figure 3.4 More images of Se and Zn distribution in cells transfected with perfect matched 
DNA 3-1 by X-ray fluorescence visualization. 
 
It seems that the distribution of Se-antisense DNA is not even in cells. This indicates that 
mRNA of GFP is located at some certain places in the cytoplasm. In most of the cells, the signals 
are close to the nucleus. However, there are still some cells with selenium signal keeping away 
from nucleus. This may indicate that these cells are in different stages of the cell cycle. And we 
could speculate the routes of mRNA transportation in this way. 
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3.3.3 Co-location of Selenium and GFP 
Figure 3.5 displays co-aggregation image of selenium and GFP in the cell transfected with 
perfect matched DNA. GFP signal was obtained by fluorescence detection. It seems that the 
aggregation spots of selenium and GFP overlap well in Figure 3.5C, which means Se-modified 
antisense DNA is located at the position where GFP was synthesized. As we mentioned the Se 
signal suggest the location of GFP mRNA, we think the spots that signal of Se and GFP overlapped 
are the place that GFP translation is taking place. In this way, we can confirm our hypothesis that 
the condensed spots of selenium signal indicate the places GFP is translating. 
 
Figure 3.5 X-ray fluorescence microscope images of cell transfected with DNA 3-1. 
(A) GFP fluorescence image;  
(B) Selenium X-ray fluorescence image;  
(C) Overlap image of Se (red color) and GFP (Green color);  
(D) Overlap image of Zn (yellow color) and GFP (Green color). 
 
3.4 Conclusion 
We observed that Se-modified perfect matched antisense DNA aggregated surrounding 
nucleus in the cytoplasm when transfected with GFP plasmid together. This phenomenon was not 
found in those cells transfected with the Se-modified control sequence. Therefore, the Se-modified 
antisense DNA is binding the target mRNA at some certain area in cells. By analyzing many cell 
images in the different stage of cell cycle, we found that condensed selenium signal spots are 
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always away from zinc signal. As we considering zinc signal as the location of nucleus in the cell, 
we think Se-modified antisense DNA blocked mRNA outside the nucleus in the cytoplasm. 
Meanwhile, the aggregating spot is also the place where GFP is condensed. This result is consistent 
with our hypothesis that the condensed spot of Se suggest the position where translation is taking 
place. In this way, we can conclude that translation is taking place at certain position in cells and 
we can use Se-modified antisense DNA as a biosensor to detect mRNA during this processing. 
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4 DNA/DNA POLMERASE COMPLEX STRUCTURE STUDY 
4.1 Introduction 
DNA polymerases exist in all organisms and replicate genome. Most research on DNA 
polymerases is based on DNA Polymerase I (Pol I) from Escherichia coli88. Pol I has three discrete 
domains and each of them has different enzymatic activity:  5’-3’ exonuclease, 3’-5’ proofreading 
exonuclease, and polymerase activity89. The large C-terminal fragment, which is known as Klenow 
fragment (KF), includes both the 3’-5’ exonuclease and polymerase domains90. The structure of 
KF was well determined last century91-92. When Pol I is binding to the DNA double strands, the 
conformation of the nucleotide is approximately that found in B-form DNA, having a C3’ endo 
sugar pucker92. 
Many other DNA polymerases from different families were well studied after Pol I 
delineated93. One of the most important family is thermostable DNA polymerase, including 
Thermus aquaticus DNA polymerase I (Taq)94 and Bacillus stearothermophilus DNA polymerase 
I (Bst)95. Those enzymes are very useful and are already widely used to amplify DNA sequences 
in polymerase chain reaction (PCR). The structure of both Taq96-97 and Bst98-99 were well 
determined.  
The large carboxy-terminal fragment of Bst maintains the polymerase catalytic activity, 
which allows direct observation of the products of several rounds of nucleotide incorporation. And 
Bst just like other Pol I, when binding to the DNA duplex, the sugar pucker of nucleotide was 
found a C3’ endo conformation, which is close to B-form DNA. 
A big challenge for protein-nucleic acid complex structure determination is that we can 
hardly get good crystals for these complexes. So we designed Se-modified-DNA. We would like 
to use well studied Bst as an example and test if our Se-modified DNA could make some changes 
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when binding to Bst DNA polymerase and whether our Se-modified DNA could facilitate the 
complex crystal growth process. This could be a big discovery that Se-modifications on nucleic 
acids could not only facilitate the crystal growth for nucleic acids themselves but also works for 
protein-nucleic acid complexes. Meanwhile, if the structure of complexes does not have significant 
changes, this could give us a different method to grow the protein-nucleic acid complex crystals 
and investigate the structure of complexes. In this way, we may solve the problem of complexes 
crystallization and determine many more structures of protein-nucleic acid complexes. 
 
4.2 Material and Method 
4.2.1 Bst DNA polymerase expression and purification 
Transformation of Bst DNA polymerase plasmid to BL21: Place Bst DNA polymerase 
plasmids and competent BL21 cell on ice bath. Add plasmid (1 μL, 200 ng/μL) to the competent 
cell and keep on ice bath for 30 min. Keep it at 42 °C water bath for 90 s. Then put it back on ice 
bath for 3 min. Add S.O.C medium (200 μL, Invitrogen) and shake at 37 °C 225 rpm for 45 min. 
Then pour 100 μL to the LB plate with ampicillin (100 μg/mL). Incubate at 37 °C overnight. 
Expression of Bst DNA polymerase: Pick single colony from the LB plate into 30 mL 
autoclaved LB broth with ampicillin (100 μg/mL). Shake at 37 °C 225 rpm overnight. Then add 
10 mL overnight incubated BL21 to each litter of 2×1 L LB broth with ampicillin (100 μg/mL) 
and shake at 37 °C 225 rpm for 3 h. Add IPTG (1 mL, 1 mol /L) to each litter of the broth to induce 
the expression of RNase H and continue shaking overnight at 20 °C. Harvest the cell by 
centrifuging at 4 °C 5,000 rpm for 30 min. Keep the precipitation at -80 °C. Dissolve the cell in 
His-tag column buffer A (20 mM Tris pH 7.4, 1 M NaCl, 10 mM Imidazole, 5% Glycerol). 
Sonicate the cells with 60 × 15 s bursts. After each 15 s sonication wait 20 s to let the suspension 
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cool down. Centrifuge at 4 °C 10,000 rpm for 30 min. Heat up the supernatant to 60-70 °C for 
about 10 min. Centrifuge again at 4 °C 10,000 rpm for 30 min. Keep the supernatant at -80 °C. 
Purification by His-tag column: Wash the column by buffer B (20 mM Tris-HCl pH 7.4, 
1 M NaCl, 300 mM Imidazole, 5% Glycerol) and followed by buffer A each for 5-column-volume. 
Load sample. Wash the column by buffer A until the UV value is flat. Then wash the column by 
10% buffer B until the UV value almost go back to the low value. Elute sample by gradient from 
buffer A to buffer B (up to 100% in 60 min). Dialyze the protein against 2 L Heparin column 
buffer A (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 2.8 mM β- Mercaptoethanol, 5% Glycerol) 
overnight. Detect the concentration of sample by UV analysis. Use ULP1 to cleavage His-tag by 
the concentration of 5 U/mg.  
Purification by Heparin column: Wash the Heparin column by buffer B (20 mM Tris-
HCl pH 7.4, 100 mM NaCl, 2.8 mM β- Mercaptoethanol, 5% Glycerol) and then buffer A (20 mM 
Tris-HCl pH 7.4, 1 M NaCl, 2.8 mM β- Mercaptoethanol, 5% Glycerol), each for 5-column-
volume. Load sample. Wash the column by buffer A until the UV value is flat. Elute sample by 
program increased buffer B (up to 100% in 60 min). Dialyze the protein against 2 L storage buffer 
(20 mM Tris pH 7.4, 2.8 mM β-mercaptoethanol, 100 mM NaCl, 5% Glycerol) overnight. 
Concentrate the sample to 24 mg/mL (0.4 mmol/L) and store the enzyme at -80 °C.  
SDS-PAGE: Prepare the gel-loading sample with protein sample (2 μL) in mixture of 
water (6 μL) and 5×loading buffer (2 μL, 250 mM Tris-HCl pH 6.8, 10% SDS, 0.02% 
bromophenol blue, 5% β-mercaptoethanol, 30% Glycerol). Load samples on 4%-15% SDS gel 
(Bio-rad) and start electrophoresis in 1 × Running buffer (3.02 g Tris base, 14.4 g glycine, 1 g 
SDS, add water to 1 L and adjust pH to 8.3) at 150 V for 40 min. Take out the gel and put in 
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Coomassie Brilliant Blue Staining Solution (Bio-Rad) in microwave for 1 min. Then put in 
destaining buffer (10% ethanol and 10% acetic acid in water) and shake at 37 °C for 1 h. 
 
4.2.2 Structure study on DNA/Bst DNA polymerase complex 
Crystallization of DNA/Bst DNA polymerase complex: 1 mM self-complementary DNA 
were annealed by first heating to 90°C for 1 min, and then allowing it to cool slowly down to 25 °C. 
The resulting DNA solution was mixed with the protein (final concentration: 24 mg/mL) at 1:1 
molar ratio. Co-crystallization of Se-DNA/RNA hybrid with RNase H was achieved by screening 
with the QIAGEN Classics Suite Kit (www.qiagen.com). By using the sitting-drop vapor diffusion 
method at 25°C, the crystals were readily obtained from the mixture #67 of the crystallization 
screen [Salt: 0.2 M Calcium acetate; Buffer: 0.1 M sodium cacodylate, pH 6.5; precipitant: 18% 
(w/v), PEG 8000]. 
Data collection and structure determination: Crystal diffraction data of the Se-
DNA/RNA/RNase H complex were collected at beamline 8.2.1 and 8.2.2 in the Advanced Light 
Source (ALS). 25% glycerol was used as cryoprotectant while X-ray data were collected under the 
liquid nitrogen stream at 100 °K. Crystal of DNA/Bst DNA polymerase complex diffracted X-rays 
to 1.80. The data were processed and scaled using HKL2000, and the structures were solved by 
molecular replacement using Phasing in CCP4i with Dr. Wei Yang solved structure (PDB# 2g8u) 
as model. The resulted model was refined using Refmac5 within CCP4i. The modified DNA was 
modeled into the structure using Coot. Metal ions and water molecules were added either 
automatically or manually using Coot. 
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4.2.3 Circular dichroism (CD) 
CD spectra: The DNA solution was prepared by diluting to 4 μM in buffer (100 mM NaCl, 
10 mM sodium phosphate pH 7.0, 0.1 mM EDTA) and then annealing by heating up to 90 °C for 
2 min and then slowly cool down to room temperature. CD spectra were recorded on a JASCO J-
1500 spectropolarimeter. Four scans of the spectrum were collected over the wavelength range 
200 - 350 nm at a scanning rate of 20 nm/min. The average of multiple scans was used for analysis. 
The scan of the buffer alone recorded at room temperature was subtracted from the average scans 
for each DNA duplex. Data were collected in units of millidegrees versus wavelength and 
normalized to total DNA concentration.  
 
4.3 Results and discussions 
4.3.1 Bst DNA polymerase expression and purification 
The large fragment of DNA polymerase I from Bacillus stearothermophilus (Klenow 
Fragment) was expressed and purified in our lab. Protein expressions were carried out in BL21 
(DE3; pLys E. coli; purchased from Invitrogen). Because the target protein is thermostable, we 
heated the sample to high temperature as a step to purify it. Under higher temperature, while many 
other proteins could be denatured and aggregated to precipitate, Bst DNA polymerase could keep 
stable and soluble in buffer solution. In this way, we can get purer protein before loading it to the 
affinity column for further purifications.  
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Figure 4.1 Bst DNA Polymerase Purification 
1: Supernatant; 2: After heating 10 min at 60 °C; 3: 1st time for Ni column; 4: After cleavage; 5: 
2nd time for Ni column (flow through); 6: Final sample. 
 
After heating and two columns purification, we got very pure Bst DNA polymerase protein 
(Figure 4.1). And it is ready for crystallization and structure studies. 
 
4.3.2 DNA/Bst DNA polymerase complex crystallization 
Four DNAs shared with same sequence (5’-CGCGAATTCGCG-3’) but modified on 
different positions were used for the comparison of DNA/Bst DNA polymerase complex 
crystallization. This sequence is well known as Dickerson dodecamer and is normally B form 
conformation, which is good for DNA polymerase binding. The sequence and MALDI-MS 
analysis information are shown in Table 4.1. 
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Table 4.1 MALDI-TOF MASS analysis of Dickerson dodecamer DNA 
# DNA Sequence Calc. [M-H+]- Observed 
4-1 5’- CGC GAA TTC GCG -3’ 3645.4 3645.4 
4-2 5’- CGC GAA TTC GCG -3’ 3724.4 3723.3 
4-3 5’- CGC GAA TTC GCG -3’ 3724.4 3725.2 
4-4 5’- CGC GAA TTC GCG -3’ 3803.3 3802.0 
 
The 0.5 mM DNA was annealed by heating up to 80°C for 2 min, and slowly cooling down 
to room temperature. Then the DNA was added to 12 mg/mL Bst DNA polymerase at 1:1 ratio. 
Crystallization screening was performed with QIAGEN Classics Suite Kit with 0.2 μL sample and 
0.2 μL crystallization buffer by sitting drop vapor diffusion method at 25 °C. The crystals were 
readily obtained overnight from the mixture #67 of the crystallization screen [Salt: 0.2 M Calcium 
acetate; Buffer: 0.1 M sodium cacodylate, pH 6.5; precipitant: 18% (w/v), PEG 8000]. Then the 
crystallization was repeated manually with 1 μL sample and 1 μL crystallization buffer equilibrate 
against 500 μL of 15% (v/v) MPD using hanging drop vapor diffusion method at 25 °C to get more 
crystals. The crystal was mounted, shock-frozen in liquid nitrogen with 25% glycerol as cryo-
protectant. The crystals are displayed in Figure 4.2. 
There were no significant differences found between native and Se-modified sequences. 
The shape and the speed of crystallization are almost the same.  
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Figure 4.2 Dickerson dodecamer DNA/Bst DNA polymerase complex crystallization 
(A) DNA 4-1; (B) DNA 4-2; (C) DNA 4-3; (D) DNA 4-4. 
 
4.3.3 DNA/Bst DNA polymerase structure study 
4.3.3.1 Dickerson dodecamer DNA/Bst DNA polymerase structure study 
The diffraction data of Dickerson dodecamer DNA/Bst DNA polymerase complex crystal 
was collected at beamline 8.2.1 and 8.2.2 of the ALS (Advanced Light Source) at the Lawrence 
Berkeley National Laboratory. Several crystals were screened to find the crystal with the best 
diffraction quality. The diffraction data were collected at 1 Å wavelength for 1 second per frame 
with 1° oscillation angle. The best resolution for all 4 different DNA template was about 1.8-2.4 
Å. The data were integrated and scaled by HKL2000.  
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The structure of Dickerson dodecamer DNA/Bst DNA polymerase complex was solved by 
molecular replacement using Phaser in CCP4. The corresponding native structure obtained by our 
lab previous work (PDB entry 4dsl; 2.45 Å resolution) with the same protein and different DNA 
sequence was used as a model. The resulting model was refined using REFMAC in CCP4 and 
Coot. After several cycles of refinement, water molecules were added either automatically or 
manually using Coot. Data collection and structure refinement statistics are given in Table 4.2.  
 
Table 4.2 Data collection and refinement statistics of Dickerson dodecamer DNA/Bst DNA 
polymerase complex 
Complex structure DNA4-1/Bst  DNA4-2/Bst  DNA4-3/Bst  DNA4-4/Bst  
Wavelength (Å) 1 
Resolution range (Å) 
50-1.85 
(1.92-1.85) 
50.0-2.13 
(2.21-2.13) 
50-2.40 
(2.49-2.40) 
50-2.18 
(2.26-2.18) 
Space group P212121 
Unit-cell a, b, c (Å) 
86.7, 94.1, 
105.0 
87.3, 94.2, 
105.8 
86.8, 94.3, 
105.8 
86.7, 94.2, 
105.8 
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Unique reflections 73185(6683) 47767(3919) 34483(3357) 45948(4496) 
Completeness (%) 99.1(91.5) 96.2 (80) 99.7 (99.1) 100 (100) 
Rmerge (%) 7.4 (43.1) 13.8 (48.3) 12.9 (50.7) 10.6 (48.7) 
I/σ(I) 32.7 (3.6) 18.5 (2.8) 20.9 (5.4) 29.5 (5.7) 
R value (%) 18.72 17.91 20.41 17.53 
Rfree (%) 22.36 22.43 25.65 22.49 
Average B value (Å2) 22.65 30.18 26.99 33.84 
R.m.s.d. bond length 
(Å) 
0.0189 0.0185 0.0160 0.0192 
R.m.s.d. bond angle 
(°) 
1.938 2.027 1.857 2.062 
 
As the structures shown of different angles in Figure 4.3, the overall structure of Dickerson 
dodecamer DNA/Bst DNA polymerase complexes are quite similar to each other despite the 
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different modifications. All four structures are superimposed very well. We believe in this case, 
the Se atom specific modifications do not change the structure of the complex as we found on 
many other different structures before.  
 
Figure 4.3 Different angle of overall structure of Dickerson dodecamer DNA/Bst DNA 
polymerase complex 
Complex with DNA 4-1 is green, DNA 4-2 is yellow, DNA 4-3 is cyan, DNA 4-4 is red. 
 
 However, we would like to know why these modified DNA duplex will not change the 
structure of Bst complexes. We use Bst complex with DNA 4-4, which has the most selenium 
atoms, as an example (Figure 4.4) to display the interaction between Bst DNA polymerase and 
DNA duplex. We found that the Bst DNA polymerase is binding to the minor groove of DNA 
duplex. However, our modification is on 5 position on thymidine which is in the major groove. 
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And we notice that there is no interaction between the yellow sphere which represent selenium 
atoms and protein in Figure 4.4. Therefore, this modification will not perturb any interaction with 
Bst binding, so this modification will not change the overall structure of Bst complex at all. 
 
Figure 4.4 Structure of Bst complex with DNA 4-4  
Yellow spheres represent selenium atoms. 
 
 Even though the Se-modifications have no impact on the structure of Bst DNA polymerase, 
we would like to compare the DNA duplexes in the structure of Bst complexes. The structures are 
displayed in Figure 4.5. Though the terminal base pairs show some slight disorder because of its 
73 
flexibility at that position, the main body parts of DNA duplexes display amazing consistency. The 
modifications on DNA duplexes do not only keep the overall structure of Bst DNA polymerase 
but also have no significant perturbation on DNA duplexes themselves.  
 
Figure 4.5 The structures of DNA duplexes in Bst complexes with Dickerson dodecamer DNA 
(A) DNA 4-1; (B) DNA 4-2; (C) DNA 4-3; (D) DNA 4-4. 
 
 Another interesting comparison we could do is to compare the structure of Dickerson 
dodecamer DNA when it crystallized by itself (PDB entry 3u2n; 1.25 Å resolution) and the 
structure of the same sequence in DNA/Bst DNA polymerase complex (Figure 4.6). Again, we 
did not find any significant differences between these two structures. We also enlarge the 
nucleotide in both structures (Figure 4.6B and D) and find that both sugar puckers are 2’-endo. 
This result indicates that Bst DNA polymerase binding will not change the conformation of 
Dickerson dodecamer DNA duplex. 
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Figure 4.6 Comparation of the structure of Dickerson dodecamer DNA in Bst complex and 
crystallized by itself 
(A) Structure of Dickerson dodecamer DNA in DNA/Bst DNA polymerase complex; 
(B) Nucleotide conformation in Dickerson dodecamer DNA in Bst complex; 
(C) Structure of Dickerson dodecamer DNA crystallized by itself; 
(D) Nucleotide conformation in Dickerson dodecamer DNA crystallized by itself. 
 
4.3.3.2 (5’-GTGTACAC-3’)2 DNA/Bst DNA polymerase complex structure study 
When Bst DNA polymerase binding to the DNA duplex, the sugar pucker of nucleotide 
was found a C3’ endo conformation, which is close to B-form DNA. However, some DNA 
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duplexes may prefer A-form conformation by its nature. We would like to know when Bst binding 
to this kind of DNA sequences, what conformation would the sugar pucker be and whether it will 
make any change if we introduce selenium atom to the A-form preferred DNA. 
For this part, four DNAs shared with the same sequence (5’-GTGTACAC-3’) but modified 
on different positions were used. This sequence was found A form conformation in crystals. The 
sequence and mass information are shown in Table 4.3. 
 
Table 4.3 MALDI-TOF MASS analysis of (5’-GTGTACAC-3’)2 DNA 
# DNA Sequence Calc. [M-H+]- Observed 
4-5 5’- GTGTACAC -3’ 2410.6 - 
4-6 5’- GTGTACAC -3’ 2489.6 2489.5 
4-7 5’- GTGTACAC -3’ 2489.6 2489.6 
4-8 5’- GTGTACAC -3’ 2568.5 2569.5 
 
Same crystallization condition was used for this (5’-GTGTACAC-3’)2 DNA/Bst DNA 
polymerase complex crystallization. The diffraction data of (5’-GTGTACAC-3’)2 DNA/Bst DNA 
polymerase complex crystal was collected at beamline 5.0.2 of the ALS (Advanced Light Source) 
at the Lawrence Berkeley National Laboratory. Several crystals were screened to find the crystal 
with the best diffraction quality. The diffraction data was collected at 1 Å wavelength for 1 second 
per frame with 0.25° oscillation angle. Data processing and structure refinement are all in the same 
way comparing with Dickerson dodecamer DNA/Bst DNA polymerase complex. Data collection 
and structure refinement statistics are given in Table 4.4. 
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Table 4.4 Data collection and refinement statistics of (5’-GTGTACAC-3’)2 DNA/Bst DNA 
polymerase complex 
Complex structure DNA4-5/Bst  DNA4-6/Bst  DNA4-7/Bst  DNA4-8/Bst  
Wavelength (Å) 1 
Resolution range (Å) 
50-2.26 
(2.34-2.26) 
50.0-2.64 
(2.73-2.64) 
50-2.38 
(2.47-2.38) 
50-2.32 
(2.40-2.32) 
Space group P212121 
Unit-cell a, b, c (Å) 
87.7, 93.7, 
106.1 
87.7, 93.8, 
106.0 
86.9, 93.8, 
106.8 
87.5, 93.8, 
106.0 
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Unique reflections 41490(4064) 26585(2627) 35893(3514) 25165(2572) 
Completeness (%) 99.7(99.1) 100 (100) 100 (100) 100 (100) 
Rmerge (%) 10.8 (52.9) 13.2 (55.8) 10.6 (53.0) 10.8 (52.3) 
I/σ(I) 27.4 (6.4) 21.8 (6.6) 31.4 (9.0) 27.7 (6.9) 
R value (%) 18.31 18.17 18.24 17.87 
Rfree (%) 22.87 23.91 23.60 23.10 
Average B value (Å2) 34.57 39.34 37.30 32.95 
R.m.s.d. bond length 
(Å) 
0.0185 0.0153 0.0173 0.0182 
R.m.s.d. bond angle 
(°) 
1.944 1.863 1.920 2.004 
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Figure 4.7 Different angle of overall structure of (5’-GTGTACAC-3’)2 DNA/Bst DNA 
polymerase complex 
Complex with DNA 4-5 is green, DNA 4-6 is yellow, DNA 4-7 is cyan, DNA 4-8 is red. 
 
The overall structures are shown in different angles in Figure 4.7. Similar to the Dickerson 
dodecamer sequences, no significant difference was found since all four structures are 
superimposed very well. And we think the reason for this consistency of those structures is the 
same, that the modifications are in the major groove while Bst DNA polymerase is binding to the 
minor groove of DNA duplexes. We use the Bst complex with most modified DNA 4-8 as an 
example to illustrate the relationship between the selenium modifications and DNA/Bst DNA 
polymerase binding interactions in Figure 4.8. 
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Figure 4.8 Structure of Bst complex with DNA 4-8 
Yellow spheres represent selenium atoms. 
 
Again, we would like to compare the (5’-GTGTACAC-3’)2 DNA duplexes in the structure 
of Bst complexes. The structures are displayed in Figure 4.9. This time the structures of DNA 
duplexes are even more similar to each other as this sequence is shorter than the sequence of 
Dickerson dodecamer and have less flexibility. As a conclusion based on this case and Dickerson 
dodecamer DNA/Bst complexes, we believe the 5-Se-T modifications will not perturb the structure 
of DNA duplexes on Bst DNA polymerase complexes regardless the sequence of the DNA. 
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Figure 4.9 The structures of DNA duplexes in Bst complexes with (5’-GTGTACAC-3’)2 DNA 
(A) DNA 4-1; (B) DNA 4-2; (C) DNA 4-3; (D) DNA 4-4. 
  
We are also interested in whether the (5’-GTGTACAC-3’)2 DNA duplex structure changes 
when binding to Bst DNA polymerase. Therefore, we compare the DNA duplex in the complex 
with the structure of the same sequence by itself (PDB entry 1d79; 1.45 Å resolution) in Figure 
4.10. It is obvious the structure of DNA duplex is completely different. We enlarged one of the 
nucleotides in the structure and found some interesting structure changes. Unlike the (5’-
GTGTACAC-3’)2 DNA duplex crystalized by itself, the sugar puckers of nucleotides in Bst 
complex are 2’-endo instead of 3’-endo, which makes the structure is similar to B-form 
conformation. What’s more, we find this conformation change in all the Bst DNA polymerase 
complexes with Se modified (5’-GTGTACAC-3’)2 DNA, which indicates that the Se-
modifications do not even have impacts on the conformation shifting of the nucleic acids in nucleic 
acid-protein complex in this case. 
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Figure 4.10 Comparation of (5’-GTGTACAC-3’)2 DNA in Bst complex and crystallized by 
itself 
(A) Structure of (5’-GTGTACAC-3’)2 DNA in DNA/Bst DNA polymerase complex; 
(B) Nucleotide conformation in (5’-GTGTACAC-3’)2 DNA in Bst complex; 
(C) Structure of (5’-GTGTACAC-3’)2 DNA crystallized by itself; 
(D) Nucleotide conformation in (5’-GTGTACAC-3’)2 DNA crystallized by itself. 
 
However, the conformation of DNA duplex in crystals may not be exactly the same as it is 
in aqueous. Although we determine the DNA duplex conformation changes for (5’-GTGTACAC-
3’)2 DNA in DNA/Bst DNA polymerase complex compared with the same sequence DNA 
crystallized by itself, it does not mean that Bst changes the conformation of DNA duplex. In this 
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way, we carried out CD spectra results to analysis the conformation of DNA duplexes in water 
solution. The results are displayed in Figure 4.11.  
 
 
Figure 4.11 CD spectra for native and Se-modified DNAs 
(A) CD spectra for native and Se-modified Dickerson dodecamer DNAs. DNA 4-1 is black, DNA 
4-2 is red, DNA 4-3 is purple, and DNA 4-4 is green; 
(B) CD spectra for native and Se-modified (5’-GTGTACAC-3’)2 DNAs. DNA 4-5 is black, DNA 
4-6 is red, DNA 4-7 is purple, and DNA 4-8 is green; 
(C) Overlapped CD spectra for native Dickerson dodecamer and (5’-GTGTACAC-3’)2 DNAs. 
DNA 4-1 is black, DNA 4-5 is red. 
(D) CD spectra for different conformations of DNA duplex100. 
 
The CD result is very interesting. First of all, the spectra of native DNA and Se-modified 
DNA are very similar to each other despite different sequences including Dickerson dodecamer 
and (5’-GTGTACAC-3’)2. This result indicates that Se-modifications does not only keep the 
structure of DNA duplex in Bst/DNA polymerase complexes in crystals but also keep the 
conformation of DNA duplexes by themselves in aqueous. On the other hand, the CD spectra of 
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these two different sequences are also much alike each other despite some small differences. When 
comparing them with the CD spectra of different DNA duplex conformations in Figure 4.11D100-
101, both of the DNA duplexes look like B-form DNA in water solution with peak at about 275 nm 
and valley at about 250 nm, despite the fact that the DNA duplexes show different conformations 
in crystallization. This result could indicate these two different sequences of DNA duplex both 
prefer B-form conformation in aqueous instead of A-form conformation. In this way, Bst may only 
trap the B-form conformation DNA duplexes in aqueous and lock their conformation while 
packing to crystals instead of changing the conformation of (5’-GTGTACAC-3’)2 duplexes when 
binding to them. (5’-GTGTACAC-3’)2 duplexes show A-form conformation when crystallized by 
themselves because only A-form DNA pack to form crystals. When DNA duplexes were packing 
in crystals, the conformation of DNA is locked. In this way, some of the DNA duplexes in aqueous 
will change the conformation from B-form to A-form so that the balance of conformations in water 
solution could be kept. This is our explanation that why the conformation of (5’-GTGTACAC-3’)2 
DNA duplexes is found A-form when crystallized by itself, while the conformation of the same 
sequence is found B-form in the crystal of DNA/Bst DNA polymerase complexes.  
 
4.4 Conclusion 
Se-modifications do not perturb the structure of the DNA duplex in Bst DNA polymerase 
complex. We co-crystallized Bst DNA polymerase with both B-form preferred Dickerson 
dodecamer and A-form preferred (5’-GTGTACAC-3’)2 DNAs with different Se-modifications 
and determined the structure of complexes. No significant structure perturbation was found 
between native DNA and Se-modified DNA in either Dickerson dodecamer or (5’-GTGTACAC-
3’)2 DNA when binding to Bst DNA polymerase. On the other hand, when Bst DNA polymerase 
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binding to DNA duplex, it trapped the B-form DNA duplexes with sugar pucker 2’-endo 
conformation in aqueous and lock the conformation for crystal growth, even if the DNA duplex 
itself may pack to crystals in A-form duplexes and lock the 3’-endo conformations.  
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APPENDIX: TABLES AND FIGURES 
The Classics Suite (Qiagen) Screen Kit Conditions 
# Salt Buffer Precipitant 
1 0.01 M Cobalt chloride 
0.1 M Sodium acetate 
pH 4.6 
1.0 M 1,6-Hexanediol 
2  
0.1 M tri-Sodium 
acetate pH 5.6 
2.5 M 1,6-Hexanediol 
3 0.2 M Magnesium chloride 0.1 M Tris pH 8.5 3.4 M 1,6-Hexanediol 
4   
5% (v/v) Isopropanol;  
2.0 M Ammonium sulfate 
5  
0.1 M HEPES sodium 
salt pH 7.5 
10% (v/v) Isopropanol;  
20% (w/v) PEG 4000 
6 0.2 M Calcium chloride 
0.1 M sodium acetate 
pH 4.6 
20% (v/v) Isopropanol 
7  
0.1M tri-Sodium 
citrate pH 5.6 
20% (v/v) Isopropanol;  
20% (w/v) PEG 4000 
8 0.2 M tri-Sodium citrate 
0.1 M HEPES sodium 
salt pH 7.5 
20% (v/v) Isopropanol 
9 0.2 M tri-Sodium citrate 
0.1 M sodium 
cacodylate pH 6.5 
30% (v/v) Isopropanol 
10 0.2 M Magnesium chloride 
0.1 M HEPES sodium 
salt pH 7.5 
30% (v/v) Isopropanol 
11 0.2 M Ammonium acetate 
0.1 M Tris-HCl pH 
8.5 
30% (v/v) Isopropanol 
12   
10% (v/v) Ethanol;  
1.5 M Sodium chloride 
13  0.1 M Tris pH 8.5 20% (v/v) Ethanol 
14   25% (v/v) Ethylene glycol 
15 0.02 M Calcium chloride 
0.1 M Sodium acetate 
pH 4.6 
30% (v/v) MPD 
16 0.2 M Sodium chloride 
0.1 M Sodium acetate 
pH 4.6 
30% (v/v) MPD 
17 0.2 M Ammonium acetate 
0.1 M tri-Sodium 
acetate pH 5.6 
30% (v/v) MPD 
18 0.2 M Magnesium acetate 
0.1 M Sodium 
cacodylate pH 6.5 
30% (v/v) MPD 
19 0.2 M tri-Sodium citrate 
0.1 M HEPES sodium 
salt pH 7.5 
30% (v/v) MPD 
20 0.5 M Ammonium sulfate 0.1 M HEPES pH 7.5 30% (v/v) MPD 
21 0.2 M Ammonium phosphate 0.1 M Tris pH 8.5 50% (v/v) MPD 
22  0.1 M HEPES pH 7.5 70% (v/v) MPD 
23  0.1 M Tris pH 8.5 25% (v/v) tert-Butanol 
24  
0.1 M tri-Sodium 
citrate pH 5.6 
35% (v/v) tert-Butanol 
25   0.4 M Ammonium phosphate 
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26  
0.1 M tri-Sodium 
citrate pH 5.6 
1.0 M Ammonium phosphate 
27  0.1M Tris·HCl pH 8.5 2.0 M Ammonium phosphate 
28  0.1 M HEPES pH 7.5 2.0 M Ammonium formate 
29  
0.1 M Sodium acetate 
pH 4.6 
2.0 M Ammonium sulfate 
30  0.1M Tris·HCl pH 8.5 2.0 M Ammonium sulfate 
31   2.0 M Ammonium sulfate 
32 0.1 M Sodium chloride 0.1 M HEPES pH 7.5 1.6 M Ammonium sulfate 
33 0.01 M Cobalt chloride 0.1 M MES pH 6.5 1.8 M Ammonium sulfate 
34 0.2 M K/Na tartate 
0.1 M tri-Sodium 
citrate pH 5.6 
2.0 M Ammonium sulfate 
35   1.0 M Imidazole pH 7.0 
36   0.4 M K/Na tartate 
37  
0.1 M HEPES sodium 
salt pH 7.5 
0.8 M K/Na tartate 
38  
0.1 M Imidazole pH 
6.5 
1.0 M Sodium acetate 
39 0.05 M Cadmium sulfate 0.1 M HEPES pH 7.5 1.0 M Sodium acetate 
40  
0.1 M Sodium 
cacodylate pH 5.6 
1.4 M Sodium acetate 
41  
0.1 M Sodium acetate 
pH 4.6 
2.0 M Sodium chloride 
42 
0.1 M Sodium phosphate; 0.1 M 
Potassium phosphate 
0.1 M MES pH 6.5 2.0 M Sodium chloride 
43  0.1 M HEPES pH 7.5 4.3 M Sodium chloride 
44  
0.1 M HEPES sodium 
salt pH 7.5 
1.4 M tri-Sodium citrate 
45   1.6 M tri-Sodium citrate pH 6.5 
46  
0.1 M HEPES sodium 
salt pH 7.5 
0.8 M Sodium phosphate 0.8 M 
Potassium phosphate 
47  
0.1 M Sodium acetate 
pH 4.6 
2.0 M Sodium formate 
48   4.0 M Sodium formate 
49  0.1 M Bicine pH 9.0 
2% (v/v) Dioxane;  
10% (w/v) PEG 20000 
50  0.1 M MES pH 6.5 
10% (v/v) Dioxane; 
1.6 M Ammonium sulfate 
51   35% (v/v) Dioxane 
52 0.5 M Sodium chloride 
0.1 M tri-Sodium 
citrate pH 5.6 
2% (v/v) Ethylene imine polymer 
53  0.1 M Tris pH 8.5 
12% (v/v) Glycerol;  
1.5 M Ammonium sulfate 
54 
0.5 M Sodium chloride; 0.01 M 
Magnesium chloride 
0.01 M CTAB  
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55 0.01 M Ferric chloride 
0.1 M tri-Sodium 
citrate pH 5.6 
10% (v/v) Jeffamine M-600 
56  0.1 M HEPES pH 7.5 20% (v/v) Jeffamine M-600 
57 0.5 M Ammonium sulfate 
0.1 M tri-Sodium 
citrate pH 5.6 
1.0 M Lithium sulfate 
58 0.01 M Nickel chloride 0.1 M Tris pH 8.5 1.0 M Lithium sulfate 
59  
0.1 M HEPES sodium 
salt pH 7.5 
1.5 M Lithium sulfate 
60  0.1 M Bicine pH 9.0 2.0 M Magnesium chloride 
61   0.2 M Magnesium formate 
62  0.1 M MES pH 6.5 1.6 M Magnesium sulfate 
63  
0.1 M Tris·HCl pH 
8.5 
8% (w/v) PEG 8000 
64  0.1 M HEPES pH 7.5 10% (w/v) PEG 8000 
65 0.5 M Lithium sulfate  15% (w/v) PEG 8000 
66 0.2 M Zinc acetate 
0.1 M Sodium 
cacodylate pH 6.5 
18% (w/v) PEG 8000 
67 0.2 M Calcium acetate 
0.1 M Sodium 
cacodylate pH 6.5 
18% (w/v) PEG 8000 
68 0.2 M Magnesium acetate 
0.1 M Sodium 
cacodylate pH 6.5 
20% (w/v) PEG 8000 
69 0.05 M Potassium phosphate  20% (w/v) PEG 8000 
70 0.2 M Ammonium sulfate 
0.1 M Sodium 
cacodylate pH 6.5 
30% (w/v) PEG 8000 
71 0.2 M Sodium acetate 
0.1 M Sodium 
cacodylate pH 6.5 
30% (w/v) PEG 8000 
72 0.2 M Ammonium sulfate  30% (w/v) PEG 8000 
73  
0.1 M HEPES sodium 
salt pH 7.5 
2% (v/v) PEG 400;  
2.0 M Ammonium sulfate 
74 0.2 M Calcium chloride 
0.1 M HEPES sodium 
salt pH 7.5 
28% (v/v) PEG 400 
75 0.1 M Cadmium chloride 
0.1 M Sodium acetate 
pH 4.6 
30% (v/v) PEG 400 
76 0.2 m Magnesium chloride 
0.1 M HEPES sodium 
salt pH 7.5 
30% (v/v) PEG 400 
77 0.2 M tri-Sodium citrate 
0.1 M Tris·HCl pH 
8.5 
30% (v/v) PEG 400 
78 0.1 M Sodium chloride 0.1 M Bicine pH 9.0 20% (w/v) PEG 550 MME 
79 0.01 M Zinc sulfate 0.1 M MES pH 6.5 25% (w/v) PEG 550 MME 
80   
10% (w/v) PEG 1000;  
10% (w/v) PEG 8000 
81   30% (w/v) PEG 1500 
82 0.01 M Nickel chloride 0.1 M Tris pH 8.5 20% (w/v) PEG 2000 MME 
83 0.2 M Ammonium sulfate 
0.1 M Sodium acetate 
pH 4.6 
30% (w/v) PEG 2000 MME 
84  
0.1 M Sodium acetate 
pH 4.6 
8% (w/v) PEG 4000 
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85 0.2 M Ammonium sulfate 
0.1 M Sodium acetate 
pH 4.6 
25% (w/v) PEG 4000 
86 0.2 M Ammonium acetate 
0.1 M Sodium acetate 
pH 4.6 
30% (w/v) PEG 4000 
87 0.2 M Ammonium acetate 
0.1 M tri-Sodium 
citrate pH 5.6 
30% (w/v) PEG 4000 
88 0.2 M Magnesium chloride 
0.1 M Tris·HCl pH 
8.5 
30% (w/v) PEG 4000 
89 0.2 M Lithium sulfate 
0.1 M Tris·HCl pH 
8.5 
30% (w/v) PEG 4000 
90 0.2 M Sodium acetate 
0.1 M Tris·HCl pH 
8.5 
30% (w/v) PEG 4000 
91 0.2 M Ammonium sulfate  30% (w/v) PEG 4000 
92 0.2 M Ammonium sulfate 0.1 M MES pH 6.5 30% (w/v) PEG 5000 MME 
93  0.1 M HEPES pH 7.5 
10% (w/v) PEG 6000;  
5% (v/v) MPD 
94   
10% (w/v) PEG 6000;  
2.0 M Sodium chloride 
95  0.1 M HEPES pH 7.5 
20% (w/v) PEG 10000;  
8% (v/v) Ethylene glycol 
96  0.1 M MES pH 6.5 12% (w/v) PEG 20000 
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Mass Spectrum for Important Sequences 
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